

Official Protocol Title:	A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV
NCT number:	NCT05393037
Document Date:	06-Jul-2022

Title Page

THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME LLC, RAHWAY, NJ, USA (MSD).

Protocol Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV

Protocol Number: 007-01

Compound Number: V116

Sponsor Name:

Merck Sharp & Dohme LLC
(hereafter called the Sponsor or MSD)

Legal Registered Address:

126 East Lincoln Avenue

P.O. Box 2000

Rahway, NJ 07065 USA

Regulatory Agency Identifying Number(s):

IND	19316
EudraCT	2021-006710-36

Approval Date: 06 July 2022

Sponsor Signatory

Typed Name:
Title:

Date

Protocol-specific Sponsor contact information can be found in the Investigator Study File Binder (or equivalent).

Investigator Signatory

I agree to conduct this clinical study in accordance with the design outlined in this protocol and to abide by all provisions of this protocol.

Typed Name:
Title:

Date

DOCUMENT HISTORY

Document	Date of Issue	Overall Rationale
Amendment 1	06-JUL-2022	The primary reason for this amendment is to update the country-specific requirements for France.
Original Protocol	24-MAR-2022	Not applicable

PROTOCOL AMENDMENT SUMMARY OF CHANGES

Amendment: 01

Overall Rationale for the Amendments:

The primary reason for this amendment is to update the country-specific requirements for France.

Summary of Changes Table:

Section # and Name	Description of Change	Brief Rationale
Section 10.7.1 Country-specific Requirements for France (Section 5.2 and Section 6.5)	Added a France-specific version of exclusion criteria and restricted concomitant therapy.	To include country-specific timeframe for prior and concomitant therapy.
Section 10.7.1 Country-specific Requirements for France (Section 5.2)	Added a France-specific version of exclusion criteria.	To clarify the exclusion criteria for protected populations.
Section 10.7.1 Country-specific Requirements for France (Section 10.5.2)	Added a France-specific version of contraception requirements for female participants.	To clarify current contraception methods allowed during the study.
Section 5.2 Exclusion Criteria, Section 6.5 Concomitant Therapy, and Section 10.5.2 Contraception Requirements	Added references to country-specific requirements in Appendix 7.	To refer to the France-specific exclusion criteria for concomitant therapies, and the clarification of contraception requirements in Appendix 7.

Section # and Name	Description of Change	Brief Rationale
Title Page Section 10.1.1 Code of Conduct for Clinical Trials	Sponsor entity name and address change.	Merck Sharp & Dohme Corp. underwent an entity name and address change to Merck Sharp & Dohme LLC, Rahway, NJ, USA. This conversion resulted only in an entity name change and update to the address.
Section 4.4 Beginning and End-of-Study Definition	Added a definition of local start of study for countries in the EEA.	To align with the EU CTR.
Section 5 Study Population	Added text related to the collection of demographic data.	To clarify the collection, use, and confidentiality of demographic data provided by the participants.
Section 8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events Section 10.3 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting	Added the requirement for investigators to document if an SAE is associated with medication error, misuse, or abuse. Definitions of medication error, misuse, and abuse were added.	Per Regulation (EU) No 536/2014 of the European Parliament and of the Council.
Section 10.1.4.3 Scientific Advisory Committee (SAC)	Scientific Advisory Committee responsibilities were updated.	To clarify Scientific Advisory Committee responsibilities.
Throughout Document	Minor administrative, formatting, grammatical, and/or typographical changes were made throughout the document.	To ensure clarity and accurate interpretation of the intent of the protocol.

Table of Contents

DOCUMENT HISTORY	3
PROTOCOL AMENDMENT SUMMARY OF CHANGES.....	4
1 PROTOCOL SUMMARY	13
1.1 Synopsis.....	13
1.2 Schema	18
1.3 Schedule of Activities.....	20
1.3.1 Schedule of Activities for Part A	20
1.3.2 Schedule of Activities for Part B	24
2 INTRODUCTION.....	25
2.1 Study Rationale.....	25
2.2 Background	26
2.2.1 Pharmaceutical and Therapeutic Background	26
2.2.2 Information on Other Study-related Therapy	27
2.2.2.1 PCV15.....	27
2.2.2.2 PPSV23	27
2.2.2.3 Pneumococcal Vaccination Guidelines.....	28
2.3 Benefit/Risk Assessment.....	28
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS	29
4 STUDY DESIGN.....	32
4.1 Overall Design	32
4.2 Scientific Rationale for Study Design.....	33
4.2.1 Rationale for Endpoints	34
4.2.1.1 Immunogenicity Endpoints.....	34
4.2.1.2 Safety Endpoints	34
4.2.1.3 Future Biomedical Research	35
4.2.2 Rationale for the Use of Comparator/Placebo	35
4.3 Justification for Dose	36
4.4 Beginning and End-of-Study Definition	36
4.4.1 Clinical Criteria for Early Study Termination	36
5 STUDY POPULATION	36
5.1 Inclusion Criteria	37
5.2 Exclusion Criteria	38
5.3 Lifestyle Considerations	40
5.4 Screen Failures	40
5.5 Participant Replacement Strategy.....	40

6	STUDY INTERVENTION.....	41
6.1	Study Intervention(s) Administered.....	41
6.1.1	Medical Devices.....	44
6.2	Preparation/Handling/Storage/Accountability	44
6.2.1	Dose Preparation.....	44
6.2.2	Handling, Storage, and Accountability.....	44
6.3	Measures to Minimize Bias: Randomization and Blinding.....	45
6.3.1	Intervention Assignment.....	45
6.3.2	Stratification.....	45
6.3.3	Blinding.....	46
6.4	Study Intervention Compliance.....	47
6.5	Concomitant Therapy.....	47
6.5.1	Rescue Medications and Supportive Care	47
6.6	Dose Modification	47
6.7	Intervention After the End of the Study.....	48
6.8	Clinical Supplies Disclosure.....	48
6.9	Standard Policies.....	48
7	DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL.....	48
7.1	Discontinuation of Study Intervention.....	48
7.2	Participant Withdrawal From the Study.....	49
7.3	Lost to Follow-up	49
8	STUDY ASSESSMENTS AND PROCEDURES.....	50
8.1	Administrative and General Procedures	52
8.1.1	Informed Consent.....	52
8.1.1.1	General Informed Consent.....	52
8.1.1.2	Consent and Collection of Specimens for Future Biomedical Research	52
8.1.1.3	Consent and Collection of Specimens for Optional Assay Development.....	52
8.1.2	Inclusion/Exclusion Criteria	53
8.1.3	Participant Identification Card.....	53
8.1.4	Medical History	53
8.1.5	Prior and Concomitant Medications Review	53
8.1.5.1	Prior Medications.....	53
8.1.5.2	Concomitant Medications	54
8.1.6	Assignment of Screening Number	54
8.1.7	Assignment of Treatment/Randomization Number	54

8.1.8	Study Intervention Administration	54
8.1.8.1	Timing of Dose Administration	55
8.1.9	Electronic Vaccination Report Card	55
8.1.10	Telephone Contact Questionnaire	55
8.1.11	Confirmation of Eligibility in Part B	56
8.1.12	Discontinuation and Withdrawal	56
8.1.12.1	Withdrawal From Future Biomedical Research	56
8.1.13	Participant Blinding/Unblinding	57
8.1.14	Calibration of Equipment	58
8.2	Immunogenicity Assessments	58
8.2.1	Multiplex Opsonophagocytic Assay	58
8.2.2	Pneumococcal Electrochemiluminescence Assay	59
8.3	Safety Assessments	59
8.3.1	Physical Examinations	59
8.3.2	Pregnancy Testing	60
8.3.3	HIV Serology, CD4+ T-cell Count, and Plasma HIV RNA Testing	60
8.3.4	Body Temperature Measurement	60
8.3.5	Postvaccination Observation Period	60
8.3.6	Clinical Safety Laboratory Assessments	61
8.4	Adverse Events, Serious Adverse Events, and Other Reportable Safety Events	61
8.4.1	Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information	62
8.4.2	Method of Detecting AEs, SAEs, and Other Reportable Safety Events	64
8.4.3	Follow-up of AE, SAE, and Other Reportable Safety Event Information	64
8.4.4	Regulatory Reporting Requirements for SAE	64
8.4.5	Pregnancy and Exposure During Breastfeeding	64
8.4.6	Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs	65
8.4.7	Events of Clinical Interest	65
8.4.8	Medical Device and Drug-device Combination Products - POCs/Malfunctions	65
8.4.9	Adverse Events on the VRC	65
8.4.9.1	Solicited Adverse Event	65
8.4.9.2	Unsolicited Adverse Events	66
8.5	Treatment of Overdose	66
8.6	Pharmacokinetics	66
8.7	Pharmacodynamics	66
8.8	Biomarkers	66

8.9	Future Biomedical Research Sample Collection	66
8.10	Optional Assay Development Blood Sample Collection	67
8.11	Medical Resource Utilization and Health Economics	67
8.12	Visit Requirements	67
8.12.1	Screening.....	67
8.12.2	Treatment Period/Vaccination Visit	67
8.12.3	Participants Discontinued From Study Intervention but Continuing to be Monitored in the Study	67
9	STATISTICAL ANALYSIS PLAN	67
9.1	Statistical Analysis Plan Summary	68
9.2	Responsibility for Analyses/In-house Blinding	69
9.3	Hypotheses/Estimation	69
9.4	Analysis Endpoints	69
9.4.1	Immunogenicity Endpoints.....	69
9.4.2	Safety Endpoints	71
9.5	Analysis Populations	73
9.5.1	Immunogenicity Analysis Populations	73
9.5.2	Safety Analysis Populations	74
9.6	Statistical Methods	74
9.6.1	Statistical Methods for Immunogenicity Analyses	74
9.6.2	Statistical Methods for Safety Analyses	76
9.6.2.1	Overall Safety Assessment	76
9.6.3	Demographic and Baseline Characteristics	78
9.7	Interim Analyses	78
9.8	Multiplicity	78
9.9	Sample Size and Power Calculations	79
9.9.1	Sample Size and Power for Immunogenicity Analyses.....	79
9.9.2	Sample Size and Power for Safety Analyses	79
9.10	Subgroup Analyses	80
9.11	Compliance (Medication Adherence)	80
9.12	Extent of Exposure	80
10	SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	81
10.1	Appendix 1: Regulatory, Ethical, and Study Oversight Considerations	81
10.1.1	Code of Conduct for Clinical Trials.....	81
10.1.2	Financial Disclosure.....	83
10.1.3	Data Protection.....	84
10.1.3.1	Confidentiality of Data	84

10.1.3.2	Confidentiality of Participant Records.....	84
10.1.3.3	Confidentiality of IRB/IEC Information.....	84
10.1.4	Committees Structure.....	85
10.1.4.1	Executive Oversight Committee.....	85
10.1.4.2	External Data Monitoring Committee	85
10.1.4.3	Scientific Advisory Committee (SAC).....	85
10.1.5	Publication Policy	85
10.1.6	Compliance with Study Registration and Results Posting Requirements ...	86
10.1.7	Compliance with Law, Audit, and Debarment	86
10.1.8	Data Quality Assurance	87
10.1.9	Source Documents	87
10.1.10	Study and Site Closure.....	88
10.2	Appendix 2: Clinical Laboratory Tests.....	89
10.3	Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting.....	90
10.3.1	Definitions of Medication Error, Misuse, and Abuse.....	90
10.3.2	Definition of AE	90
10.3.3	Definition of SAE	92
10.3.4	Additional Events Reported.....	93
10.3.5	Recording AE and SAE	93
10.3.6	Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor	98
10.4	Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up	100
10.4.1	Definitions.....	100
10.4.2	Recording, Assessing Causality, and Follow-up of PQC/Malfunctions ..	101
10.5	Appendix 5: Contraceptive Guidance.....	103
10.5.1	Definitions.....	103
10.5.2	Contraception Requirements.....	104
10.6	Appendix 6: Collection and Management of Specimens for Future Biomedical Research.....	105
10.7	Appendix 7: Country-specific Requirements	110
10.7.1	Country-specific Requirements for France.....	110
10.8	Appendix 8: Abbreviations	113
11	REFERENCES.....	115

LIST OF TABLES

Table 1	Study Interventions	42
Table 2	Approximate Blood Volumes Drawn by Study Visit and by Sample Types for Part A.....	51
Table 3	Approximate Blood Volumes Drawn by Study Visit and by Sample Types for Part B.....	51
Table 4	Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events.....	63
Table 5	Solicited Adverse Events	66
Table 6	Analysis Strategy for Immunogenicity Variables.....	76
Table 7	Analysis Strategy for Safety Parameters – Part A and Part B	77
Table 8	Within-group 95% CIs for Varying Hypothetical OPA GMTs and Varying Standard Deviations With 135 Evaluable Participants in Each Vaccination Group	79
Table 9	Protocol-required Safety Laboratory Assessments.....	89

LIST OF FIGURES

Figure 1	Study Design for Part A	18
Figure 2	Study Design for Part B	19

1 PROTOCOL SUMMARY

1.1 Synopsis

Protocol Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV

Short Title: Safety and Immunogenicity of V116 in Adults Living With HIV

Acronym: STRIDE-7

Hypotheses, Objectives, and Endpoints:

There is no hypothesis testing in this study.

The following objectives and endpoints will be evaluated in pneumococcal vaccine-naïve or pneumococcal vaccine-experienced adults ≥ 18 years of age living with HIV.

Objectives	Endpoints
Primary	
<u>Part A</u> <ul style="list-style-type: none">Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs).	<ul style="list-style-type: none">Solicited injection-site AEs from Day 1 through Day 5 postvaccinationSolicited systemic AEs from Day 1 through Day 5 postvaccinationVaccine-related serious adverse events (SAEs) from Day 1 through the duration of participation in Part A
<u>Part A</u> <ul style="list-style-type: none">Objective: To evaluate the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) postvaccination with V116 (30 days postvaccination [Day 30]) and PCV15 + PPSV23 (30 days postvaccination with the final dose in the regimen [Week 12]) within each vaccination group separately.	<ul style="list-style-type: none">Serotype-specific OPA responses<ul style="list-style-type: none">13 serotypes common between V116 and PCV15 + PPSV238 serotypes unique to V116

Objectives	Endpoints
Secondary	
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) postvaccination with V116 (Day 30) and PCV15 + PPSV23 (Week 12) within each vaccination group 	<ul style="list-style-type: none"> • Serotype-specific IgG responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific geometric mean fold rises (GMFRs) and proportions of participants with a ≥ 4-fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) and PCV15 + PPSV23 (Week 12) for both OPA and IgG responses within each vaccination group separately. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p><u>Part B</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the safety and tolerability of PCV15 as assessed by the proportion of participants with AEs for participants administered V116 in Part A. 	<ul style="list-style-type: none"> • Solicited injection-site AEs from Day 1B through Day 5B postvaccination • Solicited systemic AEs from Day 1B through Day 5B postvaccination • Vaccine-related SAEs from Day 1B through the duration of participation in Part B

Overall Design:

Study Phase	Phase 3
Primary Purpose	Prevention
Indication	Pneumococcal disease
Population	Adults ≥ 18 years of age living with HIV
Study Type	Interventional
Intervention Model	Parallel This is a multi-site study.
Type of Control	Active control
Study Blinding	<u>Part A:</u> Double-blind with in-house blinding <u>Part B:</u> Unblinded Open-label
Blinding Roles	<u>Part A:</u> Participants or Subjects Investigator Sponsor <u>Part B:</u> No Blinding
Estimated Duration of Study	The Sponsor estimates that the study will require approximately 19 months from the time the first participant (or their legally acceptable representative) provides documented informed consent until the last participant's last study-related contact. For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.

Number of Participants:

Approximately 300 participants will be randomized, with approximately 150 participants in each intervention group.

Intervention Groups and Duration:

Intervention Groups	Intervention Group Name	Vaccine	Dose Strength	Dose Frequency	Route of Admin.	Vaccination Regimen	Use
		V116	V116	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	Single dose	IM	Single dose at Visit 2 (Day 1)
Placebo			N/A	Single dose	IM	Single dose at Visit 5 (Week 8)	Placebo
PCV15			2 µg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) and 4 µg of PnPs antigen 6B	Single dose	IM	Single dose at Visit 9 (Day 1B)	Test Product
PCV15 + PPSV23		PCV15	2 µg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) and 4 µg of PnPs antigen 6B	Single dose	IM	Single dose at Visit 2 (Day 1)	Comparator
		PPSV23	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	Single dose	IM	Single dose at Visit 5 (Week 8)	Comparator
Admin.=administration; IM=intramuscular; N/A=not applicable; PCV15=VAXNEUVANCE™; PnPs=pneumococcal polysaccharide; PPSV23=PNEUMOVAX™23 Other current or former name(s) or alias(es) for study intervention(s) are as follows: V116, polyvalent pneumococcal conjugate vaccine (pPCV).							
Total Number of Intervention Groups/ Arms	2						
Duration of Participation	Each participant will participate in the study for approximately 6 months from the time the participant provides documented informed consent through the final contact in Part A. Participants who received V116 in Part A will return for participation in Part B for approximately 1 additional month.						

Study Governance Committees:

Executive Oversight Committee	Yes
Data Monitoring Committee	Yes
Clinical Adjudication Committee	No
Study governance considerations are outlined in Appendix 1.	

Study Accepts Healthy Volunteers: No

A list of abbreviations is in Appendix 8.

1.2 Schema

This is a 2-part study. Part A will be conducted in all eligible participants enrolled. Part B will be conducted in participants who received V116 in Part A. The main features of the study design are depicted in [Figure 1](#) for Part A and [Figure 2](#) for Part B.

Figure 1 Study Design for Part A





Figure 2 Study Design for Part B



eVRC=electronic Vaccination Report Card; HIV=human immunodeficiency virus;
 PCV15=VAXNEUVANCE™; RNA=ribonucleic acid; TC=telephone contact

1.3 Schedule of Activities

1.3.1 Schedule of Activities for Part A

Study Period:	Screening	Intervention and Follow-up							Notes
Visit Number:	1	2	3	4	5	6	7	8	
Visit Type:	Site Visit	Site Visit	TC	Site Visit	Site Visit	TC	Site Visit	TC	
Scheduled Time:	Screening	Day 1 (Vac. 1)	Day 7 (after Vac. 1)	Day 30 (after Vac. 1)	Week 8 (Vac 2; Day 56 after Vac. 1)	Week 9 (Day 7 after Vac. 2)	Week 12 (Day 30 after Vac. 2)	Day 180 (after Vac. 1)	The day of Vac. 1 is considered Day 1 of the study.
Visit Window:	NA	≤30 days after Visit 1	Days 7 to 10 after Visit 2 ^a	Days 30 to 44 after Visit 2 ^a	Days 56 to 70 after Visit 2 ^a	Days 7 to 10 after Visit 5 ^b	Days 30 to 44 after Visit 5 ^b	Days 166 to 194 after Visit 2 ^a	
Administrative Procedures									
Screening Procedures									
Informed Consent	X								Must be obtained before any study procedures are conducted.
Informed Consent for Optional Assay Development Blood Samples	X								Must be obtained before any sample collection.
Informed Consent for Optional FBR	X								Must be obtained before any sample collection.
Assignment of Screening Number	X								
Inclusion/Exclusion Criteria	X	X							
Blood Sample for HIV Serology	X								
Blood Sample for CD4+ T-cell Count	X			X			X		
Blood Sample for Plasma HIV RNA Testing	X			X			X		
Medical History	X	X							
Participant Identification Card	X	X							
Postrandomization Procedures									
Assignment of Randomization Number		X							
Prior/Concomitant Medication and Nonstudy Vaccination Review	X	X	X	X	X	X	X		
V116 or PCV15 Administration (Blinded)		X							

Study Period:	Screening	Intervention and Follow-up							Notes
Visit Number:	1	2	3	4	5	6	7	8	
Visit Type:	Site Visit	Site Visit	TC	Site Visit	Site Visit	TC	Site Visit	TC	
Scheduled Time:	Screening	Day 1 (Vac. 1)	Day 7 (after Vac. 1)	Day 30 (after Vac. 1)	Week 8 (Vac 2; Day 56 after Vac. 1)	Week 9 (Day 7 after Vac. 2)	Week 12 (Day 30 after Vac. 2)	Day 180 (after Vac. 1)	The day of Vac. 1 is considered Day 1 of the study.
Visit Window:	NA	≤30 days after Visit 1	Days 7 to 10 after Visit 2 ^a	Days 30 to 44 after Visit 2 ^a	Days 56 to 70 after Visit 2 ^a	Days 7 to 10 after Visit 5 ^b	Days 30 to 44 after Visit 5 ^b	Days 166 to 194 after Visit 2 ^a	
Placebo or PPSV23 Administration (Blinded)					X				
Provide Electronic Device or Configure Participant's Own Electronic Device for eVRC Data Collection		X							
Review eVRC Data With Participant			X	X		X	X		
Collect Electronic Device From Participants Who Received an Electronic Device							X		
Complete the Telephone Contact Questionnaire								X	
Safety Procedures									
Complete Physical Examination		X							Performed by investigator or medically qualified designee before study vaccine is administered.
Directed Physical Examination					X				
Pregnancy Test – if applicable		X			X				Females of reproductive potential must have a negative urine or serum test (consistent with local requirements and sensitive to ≤25 IU hCG) result before vaccination.
Body Temperature Measurement		X			X				Measured before vaccination. Participants with febrile illness within 72 hours before vaccination must be rescheduled.

Study Period:	Screening	Intervention and Follow-up							Notes
Visit Number:	1	2	3	4	5	6	7	8	
Visit Type:	Site Visit	Site Visit	TC	Site Visit	Site Visit	TC	Site Visit	TC	
Scheduled Time:	Screening	Day 1 (Vac. 1)	Day 7 (after Vac. 1)	Day 30 (after Vac. 1)	Week 8 (Vac 2; Day 56 after Vac. 1)	Week 9 (Day 7 after Vac. 2)	Week 12 (Day 30 after Vac. 2)	Day 180 (after Vac. 1)	The day of Vac. 1 is considered Day 1 of the study.
Visit Window:	NA	≤30 days after Visit 1	Days 7 to 10 after Visit 2 ^a	Days 30 to 44 after Visit 2 ^a	Days 56 to 70 after Visit 2 ^a	Days 7 to 10 after Visit 5 ^b	Days 30 to 44 after Visit 5 ^b	Days 166 to 194 after Visit 2 ^a	
Postvaccination Observation Period		X			X				Observed by blinded study-site personnel for at least 30 minutes postvaccination.
AE Monitoring	X	X	X	X	X	X	X	X	Nonserious AEs collected through Day 30 after each vaccination. SAEs and deaths collected through the duration of participation in Part A. See Section 8.4.1 for further details.
Immunogenicity Procedures									
Serum for Immunogenicity Assays		X		X			X		Day 1 samples should be collected before vaccination.
Future Biomedical Research									
Blood (DNA) for FBR		X							For participants who provided FBR consent. Should be collected before vaccination at Visit 2, or at a later date as long as FBR consent is obtained prior to collection.
Assay Development Samples									
Serum for Optional Assay Development		X		X			X		For participants who provided consent for optional assay development. Visit 2 sample should be collected before vaccination.

Study Period:	Screening	Intervention and Follow-up							Notes
Visit Number:	1	2	3	4	5	6	7	8	
Visit Type:	Site Visit	Site Visit	TC	Site Visit	Site Visit	TC	Site Visit	TC	
Scheduled Time:	Screening	Day 1 (Vac. 1)	Day 7 (after Vac. 1)	Day 30 (after Vac. 1)	Week 8 (Vac 2; Day 56 after Vac. 1)	Week 9 (Day 7 after Vac. 2)	Week 12 (Day 30 after Vac. 2)	Day 180 (after Vac. 1)	The day of Vac. 1 is considered Day 1 of the study.
Visit Window:	NA	≤30 days after Visit 1	Days 7 to 10 after Visit 2 ^a	Days 30 to 44 after Visit 2 ^a	Days 56 to 70 after Visit 2 ^a	Days 7 to 10 after Visit 5 ^b	Days 30 to 44 after Visit 5 ^b	Days 166 to 194 after Visit 2 ^a	

AE=adverse event; eVRC=electronic Vaccination Report Card; FBR=future biomedical research; hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; NA=not applicable; PCV15=VAXNEUVANCE™; PPSV23=PNEUMOVAX™23; RNA=ribonucleic acid; SAE=serious adverse event; TC=telephone contact; Vac.=vaccination

^a When scheduling Visits 3, 4, 5, and 8, “Day 1” is the date of Visit 2.

^b When scheduling Visits 6 and 7, “Day 1” is the date of Visit 5.

1.3.2 Schedule of Activities for Part B

Study Period:	Intervention and Follow-up			Notes
Visit Number:	9	10	11	
Visit Type:	Site Visit	TC	Site Visit	
Scheduled Time:	Day 1B	Day 7B	Day 30B	
Visit Window:	≤3 months post Part A DBL	Days 7B to 10B	Days 30B to 44B	
Administrative Procedures				
Confirmation of Eligibility in Part B	X			
Blood Sample for CD4+ T-cell Count	X		X	
Blood Sample for Plasma HIV RNA Testing	X		X	
Prior/Concomitant Medication and Nonstudy Vaccination Review	X	X	X	
PCV15 Administration (Open-label)	X			
Provide Electronic Device or Configure Participant's Own Electronic Device for eVRC Data Collection	X			
Review eVRC Data With Participant		X	X	
Collect Electronic Device From Participants Who Received an Electronic Device			X	
Safety Procedures				
Directed Physical Examination	X			Performed by the investigator or medically qualified designee before study vaccine is administered.
Pregnancy Test – if applicable	X			Females of reproductive potential must have a negative urine or serum test (consistent with local requirements and sensitive to ≤25 IU hCG) result before vaccination.
Body Temperature Measurement	X			Measured before vaccination. Participants with febrile illness within 72 hours before vaccination must be rescheduled.
Postvaccination Observation Period	X			Observed by study-site personnel for at least 30 minutes postvaccination.
AE Monitoring	X	X	X	Nonserious AEs and SAEs collected through the duration of Part B.
Immunogenicity Procedures				
Serum for Immunogenicity Assays	X		X	Visit 9 samples should be collected before vaccination.
Assay Development Samples				
Serum for Optional Assay Development	X		X	For participants who provided consent for optional assay development. Visit 9 sample should be collected before vaccination.
AE=adverse event; DBL=database lock; eVRC=electronic Vaccination Report Card; hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; NA=not applicable; PCV15=VAXNEUVANCETM; RNA=ribonucleic acid; SAE=serious adverse event; TC=telephone contact				

2 INTRODUCTION

The Sponsor is developing an investigational polyvalent pneumococcal 21-valent conjugate vaccine (V116) for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

2.1 Study Rationale

Streptococcus pneumoniae is a major cause of vaccine-preventable disease worldwide. It is associated with considerable morbidity and mortality with the highest burden seen in children <5 years and adults >70 years of age [Troeger, C., et al 2018]. PCV vaccination has reduced the incidence of disease caused by vaccine serotypes in the age groups being vaccinated (primarily children <5 years of age in most countries) and has had an indirect effect in other age groups.

However, an unmet medical need exists as increases in IPD due to serotypes not included in licensed PCVs have been observed in several countries, especially in adults.

V116 is an investigational PCV designed to address this unmet need and includes *S pneumoniae* serotypes not included in licensed PCVs. The serotypes in V116 account for the majority of IPD observed in adults.

Persons living with HIV are at an increased risk of IPD compared with uninfected individuals. This risk remains elevated even in individuals on combined ART and with a high CD4+ T-cell count and suppressed viral load [Garcia Garrido, H. M., et al 2020]. Currently, treatment guidelines in many countries recommend the use of a PCV as part of a sequential regimen with PPSV23 for persons living with HIV. Specifically, in October 2021, the US ACIP recommended pneumococcal vaccination either with a sequential regimen of PCV15 followed by PPSV23 or with a single dose of PCV20 to adults 19 to 64 years of age with chronic medical conditions or immunocompromising conditions which confer an increased risk of pneumococcal disease [Kobayashi, M., et al 2022]. Many countries and regions follow similar recommendations (sequential regimen of PCV13 followed by PPSV23 or PPSV23 alone) for adults with certain conditions at increased risk of pneumococcal disease [Castiglia P. 2014] [Bonnave, C., et al 2019].

Adults at high risk for pneumococcal disease due to underlying comorbid conditions such as HIV, may benefit from receiving V116, which contains 21 serotypes. The serotypes in V116 are expected to provide broader protection against pneumococcal disease and offer an advantage due to being a conjugate vaccine, which includes induction of a memory immune response.

This clinical study is designed to evaluate the safety, tolerability, and immunogenicity of V116 in persons living with HIV who are ≥ 18 years of age with a CD4+ T-cell count ≥ 50 cells/ μ L and a plasma HIV RNA value <50,000 copies/mL prior to study entry. Participants with or without prior pneumococcal vaccination experience will be eligible for enrollment (see Section 5.1).

This study will be conducted in 2 parts (see Section 4.2):

- Part A will evaluate V116 and the comparator regimen of PCV15 followed by PPSV23 to provide safety and immunogenicity data of V116 with respect to a regimen that is currently recommended by the US ACIP and for which there are data available in the population targeted in this study.
- Part B will evaluate PCV15 in participants who received V116 in Part A to provide safety and immunogenicity data in a high-risk population who may also benefit from vaccination with serotypes that are included in PCV15.

2.2 Background

To date, a Phase 1/Phase 2 study (V116-001) and a Phase 1 study in Japan (V116-002) have been conducted with V116. Results from the Phase 1 part of V116-001 were used to select the optimal vaccine formulation for subsequent development. Results from these studies showed that V116 is immunogenic and has acceptable safety and tolerability in healthy adults. Refer to the IB for detailed background information on V116.

2.2.1 Pharmaceutical and Therapeutic Background

Pneumococcal disease (ie, disease caused by *S pneumoniae*) is one of the single largest vaccine-preventable causes of death in children and older adults (≥ 65 years of age) worldwide. PCV use in children has decreased the incidence of disease caused by vaccine serotypes and has led to indirect protection in unvaccinated individuals from other age groups. This has resulted in decreased hospital admissions for pneumococcal disease in adults ≥ 65 years of age, including estimated decreases of 29% and 34% in admissions due to IPD and noninvasive pneumococcal pneumonia, respectively [Simonsen, L., et al 2014]. In some countries, including the US, the decrease in pneumococcal disease in children vaccinated with PCV has led to the recommendation to vaccinate adults with PCVs. However, current surveillance does not definitively indicate that the use of PCVs in adults results in a similar reduction in pneumococcal disease [Matanock, A. 2018]. The residual burden of disease in the US is estimated as 24 cases of IPD per 100,000 in adults ≥ 65 years of age, and surveillance data estimates serotypes included in currently licensed PCVs account for approximately 23% to 50% of these cases [Centre for Disease Control and Prevention 2016] [Centers for Disease Control and Prevention 2019] [Kobayashi, M. 2021].

The residual burden of disease in adults reflects the difference in serotype distribution in adults compared with infants and children. An increasing incidence of disease due to serotypes not included in the licensed PCVs has been observed, particularly in adults [Miller, Elizabeth, et al 2011] [Moore, M. R., et al 2015] [Pilishvili, T. 2015] [van der Linden, M., et al 2015] [Golden, A. R., et al 2016]. Increases in IPD cases due to nonvaccine serotypes (3, 7F, and 19A after implementation of PCV7; 22F and 33F following widespread usage of PCV13) have been observed in both pediatric and older adult (≥ 65 years of age) populations in the US [Hicks, L. A., et al 2007] [Pilishvili, Tamara, et al 2010] [Waight, P. A., et al 2015] [Moore, M. R., et al 2015] [Demczuk, W. H. B., et al 2013]. Similarly, due to the limited serotype coverage of the currently licensed vaccines in the EU, serotype replacement due to

nonvaccine serotypes is being observed in older adults and may decrease the potential additional benefit of vaccination with currently available PCVs [European Center for Disease Prevention and Control 2018].

Serotypes were selected for inclusion in V116 based on available global epidemiology data with a primary focus on data from older adults (≥ 65 years of age) in the US and EU, regions with an established pediatric vaccination program. Based on 2018 surveillance data in US adults ≥ 65 years of age, the serotypes selected for inclusion in V116 account for approximately 83% of all cases of IPD, 25% to 30% of which are accounted for by the serotypes unique to V116 (US CDC ABCs unpublished data 2014 to 2018) [Centre for Disease Control and Prevention 2018].

V116 includes serotypes not currently contained in any licensed pneumococcal vaccine. It is being developed to support an indication for active immunization for the prevention of invasive disease and pneumonia caused by *S pneumoniae* serotypes 3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults ≥ 18 years of age. Note that serotype 15C represents deOAc15B as the molecular structures for deOAc15B and 15C are similar.

2.2.2 Information on Other Study-related Therapy

2.2.2.1 PCV15

Refer to approved labeling for detailed background information on PCV15.

PCV15 is a pneumococcal conjugate vaccine that includes 15 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) individually conjugated to the CRM₁₉₇ and formulated with aluminum phosphate adjuvant.

PCV15 is approved for use in the US, EU, and other countries in adults ≥ 18 years of age for the prevention of pneumococcal disease caused by the serotypes in the vaccine (indication may vary by country).

2.2.2.2 PPSV23

Refer to approved labeling for detailed background information on PPSV23.

PPSV23 is comprised of the polysaccharides from 23 of the serotypes causing disease in adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F). The formulation is not adjuvanted and no carrier protein is used.

PPSV23 was first approved in the US in 1983 and is now licensed in >50 countries worldwide. PPSV23 is indicated for the prevention of pneumococcal disease in adults ≥ 50 years of age and in individuals ≥ 2 years of age at increased risk for pneumococcal disease.

2.2.2.3 Pneumococcal Vaccination Guidelines

Many countries have implemented age-based and/or risk-based recommendations for pneumococcal vaccination. Age-based recommendations typically start at 65 years of age due to the increased risk of pneumococcal disease associated with age.

Prior to 2014, the US ACIP recommended that all adults ≥ 65 years of age receive a single dose of PPSV23. In 2014, ACIP recommended the sequential vaccination regimen of PCV13 followed by PPSV23 for all adults ≥ 65 years of age, with the intent to reevaluate this recommendation. The guideline was updated in 2019 to remove the recommendation for routine use of PCV13 among adults ≥ 65 years and continued to recommend a routine single dose of PPSV23 for adults aged ≥ 65 years [Matanock, A., et al 2019]. The ACIP updated the guidelines in 2021 to recommend that adults ≥ 65 years of age should receive either PCV15 followed by PPSV23, or PCV20 alone [Kobayashi, M., et al 2022].

Risk-based recommendations generally include individuals with an increased risk of pneumococcal disease who are categorized as immunocompetent at-risk or as high-risk. Conditions associated with immunocompetent at-risk include, but are not limited to, chronic heart disease, chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), diabetes mellitus, alcoholism, chronic liver disease (including cirrhosis), and cigarette smoking. Conditions associated with high-risk include, but are not limited to, congenital or acquired asplenia, sickle cell disease/other hemoglobinopathies, chronic renal failure, congenital or acquired immunodeficiencies, generalized malignancy, hematologic malignancy, HIV infection, nephrotic syndrome, solid organ transplant, and hematopoietic stem cell transplant [Kobayashi, M., et al 2022]. In the US, recommendations for immunocompetent at-risk individuals 19 to 64 years of age previously included a single dose of PPSV23, with the exception of individuals with cochlear implants or CSF leaks, who should receive PCV13 followed by PPSV23. High-risk individuals were recommended to receive 1 dose of PCV13 followed by 1 dose of PPSV23 ≥ 8 weeks later, and an additional dose of PPSV23 ≥ 5 years later [Matanock, A., et al 2019]. Similar to the age-based recommendations, the ACIP guidelines were updated in 2021, and now recommend that immunocompetent at-risk individuals and high-risk individuals 19 to 64 years of age receive PCV15 followed by PPSV23, or PCV20 alone [Kobayashi, M., et al 2022].

2.3 Benefit/Risk Assessment

It cannot be guaranteed that participants in clinical studies will directly benefit from administration of V116, as clinical studies are designed to provide information about the safety and effectiveness of an investigational medicine.

Despite the public health impact of currently available pneumococcal vaccines, pneumococcal disease in adults remains an unmet medical need. *S pneumoniae* is a major cause of vaccine-preventable disease worldwide, resulting in considerable morbidity and mortality [Troeger, C., et al 2018].

Vaccination with PCVs has reduced the incidence of disease caused by vaccine serotypes in the population targeted by the vaccination (primarily children < 5 years of age in most

countries) and has had an indirect effect in other age groups. However, in several countries, infant vaccination with PCVs has also led to increases in IPD due to serotypes not included in the licensed PCVs, particularly in adults.

V116 is designed to provide broader pneumococcal disease coverage in adults compared with currently licensed pneumococcal vaccines and is anticipated to have a generally comparable safety profile. No clinically important safety findings have been identified to date based on data from early phase clinical studies with V116.

The benefit-risk profile for V116 supports continued evaluation.

In this study, approximately 50% of participants will receive PCV15 followed by PPSV23. V116 is expected to provide comparable immune responses to PCV15 + PPSV23 for the serotypes in common with either PCV15 or PPSV23 while providing additional coverage for the serotypes unique to V116. It is unknown if V116 will have the same clinical benefit as PCV15 + PPSV23. Participants who received V116 in Part A may benefit from vaccination with serotypes that are included in PCV15 by receiving PCV15 in Part B.

Additional details regarding specific benefits and risks for participants participating in this clinical study may be found in the accompanying IB and informed consent documents.

3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS

There is no hypothesis testing in this study.

The following objectives and endpoints will be evaluated in pneumococcal vaccine-naïve or pneumococcal vaccine-experienced adults ≥ 18 years of age living with HIV.

Objectives	Endpoints
Primary	
<p><u>Part A</u></p> <ul style="list-style-type: none">• Objective: To evaluate the safety and tolerability of V116 as assessed by the proportion of participants with adverse events (AEs).	<ul style="list-style-type: none">• Solicited injection-site AEs from Day 1 through Day 5 postvaccination• Solicited systemic AEs from Day 1 through Day 5 postvaccination• Vaccine-related serious adverse events (SAEs) from Day 1 through the duration of participation in Part A

Objectives	Endpoints
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) postvaccination with V116 (30 days postvaccination [Day 30]) and PCV15 + PPSV23 (30 days postvaccination with the final dose in the regimen [Week 12]) within each vaccination group separately. 	<ul style="list-style-type: none"> • Serotype-specific OPA responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p>Secondary</p>	
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific Immunoglobulin G (IgG) geometric mean concentrations (GMCs) postvaccination with V116 (Day 30) and PCV15 + PPSV23 (Week 12) within each vaccination group 	<ul style="list-style-type: none"> • Serotype-specific IgG responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific geometric mean fold rises (GMFRs) and proportions of participants with a ≥ 4-fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) and PCV15 + PPSV23 (Week 12) for both OPA and IgG responses within each vaccination group separately. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p><u>Part B</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the safety and tolerability of PCV15 as assessed by the proportion of participants with AEs for participants administered V116 in Part A. 	<ul style="list-style-type: none"> • Solicited injection-site AEs from Day 1B through Day 5B postvaccination • Solicited systemic AEs from Day 1B through Day 5B postvaccination • Vaccine-related SAEs from Day 1B through the duration of participation in Part B

Objectives	Endpoints
Tertiary/Exploratory	
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) compared with PCV15 + PPSV23 (Week 12). 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses <ul style="list-style-type: none"> ○ 13 serotypes common between V116 and PCV15 + PPSV23 ○ 8 serotypes unique to V116
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) and PCV15 (Day 30), and evaluate serotype-specific GMFRs and proportions of participants with a ≥ 4-fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) and PCV15 (Day 30) within each vaccination group separately. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses <ul style="list-style-type: none"> ○ 6 serotypes common between V116 and PCV15 ○ 15 serotypes unique to V116
<p><u>Part A</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the cross-reactive immune responses to serotypes within a serogroup 30 days postvaccination. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses
<p><u>Part B</u></p> <ul style="list-style-type: none"> • Objective: To evaluate the serotype-specific OPA and IgG responses 30 days postvaccination with PCV15 for participants administered V116 in Part A. 	<ul style="list-style-type: none"> • Serotype-specific OPA and IgG responses <ul style="list-style-type: none"> ○ 6 serotypes common between V116 and PCV15 ○ 15 serotypes unique to V116 ○ 9 serotypes included in PCV15 but not in V116

4 STUDY DESIGN

4.1 Overall Design

This is a 2-part study.

Part A

Part A is a randomized, active comparator-controlled, parallel-group, multisite, double-blind study of V116 in participants ≥ 18 years of age living with HIV.

Approximately 300 participants will be randomized in a 1:1 ratio to receive either V116 on Day 1 followed by placebo 8 weeks later, or PCV15 on Day 1 followed by PPSV23 8 weeks later. Randomization will be stratified by prior pneumococcal vaccination status (PCV13 and PPSV23 naïve; prior PCV13 only; prior PPSV23 only or prior PCV13 and PPSV23) and by CD4+ T-cell count at Screening (≥ 50 to < 500 cells/ μL ; ≥ 500 cells/ μL). Approximately 50% of participants will be naïve to PCV13 and PPSV23.

An eVRC will be used by all participants to record solicited injection-site AEs, solicited systemic AEs, and daily body temperature from Day 1 through Day 5 following each vaccination. Unsolicited AEs will be collected from Day 1 through Day 30 following each vaccination. All participants will be provided with an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

Information for SAEs and deaths, regardless of whether the events are considered to be vaccine-related by the investigator, will be collected through the duration of participation in Part A. See Section 8.4.1 for further details.

Blood samples for immunogenicity assays will be drawn on Day 1, Day 30, and Week 12.

Upon completion of Part A, the database will be locked, and the Sponsor, investigators, and participants will be unblinded. An analysis for Part A will be performed at this point. These data will be considered final for Part A.

Part B

Part B will be initiated upon database lock and unblinding of Part A. Participants who received V116 in Part A will receive PCV15, open-label, in Part B and will be followed for 30 days. The interval between V116 and PCV15 administration will range from approximately 10 to 18 months based upon when each participant was enrolled in Part A and when each participant returned for Part B. An eVRC will be used by participants to record solicited injection-site, solicited systemic AEs, and daily body temperature from Day 1B through Day 5B postvaccination. Unsolicited AEs will be recorded from Day 1B through Day 30B postvaccination. SAEs will be collected from Day 1B through the duration of participation in Part B. Blood samples for immunogenicity assays will be drawn on the day of vaccination and at 30 days postvaccination.

Part A and Part B

An external DMC will conduct a periodic review of safety and tolerability data for the V116 Phase 3 program. A description of the structure and function of the DMC, along with the timing and content of the safety reviews, will be outlined in the DMC charter. Information regarding the composition of the DMC is provided in Appendix 1.

Specific procedures to be performed during the study, including prescribed times and associated visit windows, are outlined in Section 1.3.1 (Part A) and Section 1.3.2 (Part B) of the SoA. Details of each procedure are provided in Section 8.

4.2 Scientific Rationale for Study Design

Individuals living with HIV are at an increased risk of IPD compared with HIV uninfected individuals. This study will be conducted in adults ≥ 18 years of age living with HIV, with or without prior pneumococcal vaccination experience, and with a documented CD4+ T-cell count ≥ 50 cells/ μL as well as plasma HIV RNA $< 50,000$ copies/mL prior to study entry. This study is designed to assess safety, tolerability, and immunogenicity in a representative population whom vaccination with a pneumococcal vaccine is recommended.

This study aims to enroll participants with CD4+ T-cell counts ≥ 50 cells/ μL . Due to early initiation of ART, the majority of participants are expected to have CD4+ T-cell counts > 200 cells/ μL . Participants with CD4+ T-cell count < 50 cells/ μL or plasma HIV RNA $\geq 50,000$ copies/mL will be excluded based on the accepted clinical practice of prioritizing ART prior to vaccination. HIV is considered an immunocompromising condition, in which the degree of immunosuppression is directly related to the CD4+ T-cell count. CD4+ T-cell count at the time of study vaccination may impact the immune response of the study vaccine, with lower CD4+ T-cell counts having more of an impact on the ability of the immune system to respond to the vaccine; thus, CD4+ T-cell counts will be used as a stratification factor (see Section 6.3.2). Additionally, CD4+ T-cell counts and HIV RNA will be monitored during the study as indicated in Sections 1.3.1 and 1.3.2 to provide information on the immune status of the participants following study vaccination.

Pneumococcal vaccine-experienced participants (based on prior PCV13 and PPSV23 vaccination history; see Section 5.1) are included in this study to provide data on the impact of prior vaccination in a population that may benefit from additional vaccination with V116. Prior vaccination history will be included as a stratification factor (see Section 6.3.2). Participants who received PCV7 will be eligible for this study. PCV7 was largely approved and in recommendation guidelines in 2000, thus, there will be some participants who received PCV7 and are ≥ 18 years of age that are eligible for this study. Prior receipt of PCV7 is not expected to impact the immunogenicity analysis of V116 serotypes as there are no common serotypes between PCV7 and V116 or PPSV23, and only serotypes included in V116 will be analyzed.

Individuals who received PCV10 as part of their pediatric vaccination schedule will not be eligible for this study as these individuals will be < 18 years of age at the time of study initiation. PCV10 was approved first in Canada in December 2008 and then approved by the

EMA in March 2009. PCV10 was approved as a 2-dose series administered prior to 12 months of age or as a booster dose prior to 5 years of age.

Part A will evaluate V116 and the comparator regimen of PCV15 followed by PPSV23 to provide safety and immunogenicity data of V116 with respect to a regimen that is currently recommended by the US ACIP and for which there are data available in the population targeted in this study.

Part B will evaluate PCV15 in participants who received V116 in Part A to provide safety, tolerability, and immunogenicity data in a high-risk population who may also benefit from vaccination with serotypes that are included in PCV15.

4.2.1 Rationale for Endpoints

4.2.1.1 Immunogenicity Endpoints

The immunogenicity endpoints are consistent with previous studies evaluating PCVs.

Sera from participants will be used to assess vaccine-induced, anti-PnPs serotype-specific OPA and IgG responses using the validated MOPA and Pn ECL assay, respectively. Immunogenicity endpoints will be evaluated for all serotypes included in V116 and for cross-reactive serotypes within a serogroup.

Several studies have shown a positive correlation between serotype-specific IgG antibody concentrations and OPA titers in children and adults [Centers for Disease Control and Prevention 2010] [Anttila, M., et al 1999] [Romero-Steiner, S., et al 1997]. OPA assesses levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides for presentation to phagocytic cells for engulfment and subsequent killing, and therefore is considered an important immunologic surrogate for protection against IPD in adults. It is noted that IgG antibody concentration and OPA titer threshold values that correlate with protection in adults have not been defined; however, the OPA responses are considered accepted endpoints for the evaluation of novel pneumococcal vaccines in adults.

The OPA GMT, IgG GMC, GMFRs, and proportion of participants with 4-fold rise in OPA and IgG responses are acceptable assessments used to evaluate novel PCVs.

Details on the immunogenicity endpoints evaluated in this study can be found in Section 9.4.1.

4.2.1.2 Safety Endpoints

Safety information will be collected from all participants on an eVRC. The eVRC used to record AEs during the postvaccination periods (Section 8.1.9) is structured as recommended in the final US FDA Patient-reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The safety endpoints (ie, AEs and temperature) evaluated in this study are consistent with previous studies of V116 and published data from marketed PCVs. Detailed information for the safety endpoints evaluated in this study can be found in Section 9.4.2.

Definitions and reporting requirements for AEs are provided in Appendix 3.

4.2.1.3 Future Biomedical Research

The Sponsor will conduct FBR on specimens for which consent was provided during this study. This research may include genetic analyses (DNA), gene expression profiling (RNA), proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, depending on which specimens are consented for FBR.

Such research is for biomarker testing to address emergent questions not described elsewhere in the protocol and will only be conducted on specimens from appropriately consented participants. The objective of collecting/retaining specimens for FBR is to explore and identify biomarkers that inform the scientific understanding of diseases and/or their therapeutic treatments. The overarching goal is to use such information to develop safer, more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of the correct drug/vaccine at the correct time. The details of FBR research are presented in Appendix 6.

4.2.2 Rationale for the Use of Comparator/Placebo

Placebo-controlled clinical studies for new PCVs are no longer practical given the proven clinical efficacy and widespread use of licensed pneumococcal vaccines worldwide.

The sequential regimen of a PCV followed by PPSV23 is recommended in many countries for individuals at increased risk for pneumococcal disease [Nuorti, J. P. and Whitney, C. G. 2010] [Robert Koch Institut 2017]. In Part A, the comparator regimen is PCV15 followed by PPSV23 (PCV15 + PPSV23). This comparator is supported because the regimen of PCV15 followed by PPSV23 has been evaluated in the population of persons living with HIV and includes the most serotypes directed against pneumococcal disease compared with other licensed vaccines [Mohapi, L., et al 2021]. The sequential regimen of PCV15 + PPSV23 has 13 serotypes in common with V116: 6 serotypes (3, 6A, 7F, 19A, 22F, 33F) contained in PCV15 and 7 serotypes (8, 9N, 10A, 11A, 12F, 17F, 20) contained in PPSV23 but not included in PCV15. V116 contains 8 unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31, 35B) not included in any licensed pneumococcal vaccine. Note that serotype 15C represents deOAc15B as the molecular structures for deOAc15B and 15C are similar.

Placebo is used in this study to maintain blinding. The placebo is sterile saline for injection.

In Part B, participants who received V116 in Part A will receive PCV15 open-label. Participants who received PCV15 + PPSV23 will not proceed to Part B.

4.3 Justification for Dose

The V116 dose of 4 µg/each PnPs was selected based on review of safety and immunogenicity data from the Phase 1 and Phase 2 studies. In Phase 1, 2 doses of V116 were evaluated: a single dose containing 2 µg/each PnPs and a single dose of 4 µg/each PnPs. Based on the data from Phase 1, the V116 dose of 4 µg/each PnPs was selected for further evaluation in Phase 2. Results from Phase 2 showed that the V116 dose of 4 µg/each PnPs is well tolerated and generates serotype-specific immune responses. These data support the selection of the V116 dose of 4 µg/each PnPs for further development in Phase 3.

Refer to the IB for detailed background information on V116.

The doses of PCV15 and PPSV23 selected for use in this study are the approved doses that are consistent with the approved US and EU dosing and product labeling of VAXNEUVANCE™ and PNEUMOVAX™23, respectively.

4.4 Beginning and End-of-Study Definition

The overall study begins when the first participant (or their legally acceptable representative) provides documented informed consent. The overall study ends when the last participant completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the participant is unable to be contacted by the investigator).

For purposes of analysis and reporting, the overall study ends when the Sponsor receives the last laboratory result or at the time of final contact with the last participant, whichever comes last.

If the study includes countries in the European Economic Area (EEA), the local start of the study in the EEA is defined as First Site Ready (FSR) in any Member State.

4.4.1 Clinical Criteria for Early Study Termination

The clinical study may be terminated early if the extent (incidence and/or severity) of emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or other applicable regulatory requirements, procedure-related problems or the number of discontinuations for administrative reasons is too high.

5 STUDY POPULATION

As stated in the Code of Conduct for Clinical Trials (Appendix 1.1), this study includes participants of varying age (as applicable), race, ethnicity, and sex (as applicable). The collection and use of these demographic data will follow all local laws and participant confidentiality guidelines while supporting the study of the disease, its related factors, and the IMP under investigation.

Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.

5.1 Inclusion Criteria

A participant is eligible for inclusion in the study if the participant meets all of the following criteria:

Type of Participant and Disease Characteristics

1. Is infected with HIV and has a CD4+ T-cell count ≥ 50 cells/ μ L and plasma HIV RNA $< 50,000$ copies/mL tested at Screening (Visit 1).
2. Is receiving combination ART for ≥ 6 weeks before study entry with no intended changes to combination ART therapy for 3 months after randomization.
3. Is vaccine-naïve (participant who has never received PCV13 and PPSV23), or vaccine-experienced (participant who has received PCV13 ≥ 8 weeks, or PCV13 + PPSV23 ≥ 4 years, or PPSV23 ≥ 4 years before Visit 2 [Day 1]).

Demographics

4. Is male or female, ≥ 18 years of age, at the time of informed consent.

Female Participants

5. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
 - Not a WOCBP
 - OR
 - A WOCBP and:
 - Uses an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), as described in Appendix 5 during the intervention period and for at least 6 weeks after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (ie, noncompliance, recently initiated) in relationship to the first dose of study intervention. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. **Note:** Use of an acceptable contraceptive method is required during the intervention period and for at least 6 weeks after the last dose of study intervention in **Part A** of the study only.
 - Has a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. If a urine test

cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive. Additional requirements for pregnancy testing during and after study intervention are in Section 8.3.2.

- Medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a woman with an early undetected pregnancy.

Informed Consent

6. The participant (or legally acceptable representative) has provided documented informed consent for the study. The participant may also provide documented informed consent for FBR and/or assay development sample collection. However, the participant may be enrolled in the study without providing consent for FBR or assay development sample collection.

Additional Categories

7. The participant has the ability to complete eVRC data collection without assistance based on judgment of the investigator.

5.2 Exclusion Criteria

The participant must be excluded from the study if the participant meets any of the following criteria:

Medical Conditions

1. Has a history of opportunistic infections ≤ 12 months before the first vaccination at Visit 2 (Day 1) (applicable to Part A) and before vaccination at Visit 9 (Day 1B) (applicable to Part B).
2. Has a history of noninfectious acquired immune deficiency syndrome-related illness such as Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy.
3. *Has a history of active hepatitis with elevation in pretreatment aspartate transaminase or alanine transaminase values $> 5 \times$ the upper limit of normal ≤ 6 months before the first vaccination at Visit 2 (Day 1) (applicable to Part A) and before vaccination at Visit 9 (Day 1B) (applicable to Part B).
4. Has a history of IPD (positive blood culture, positive CSF culture, or positive culture at another sterile site) or known history of other culture-positive pneumococcal disease ≤ 3 years before Visit 2 (Day 1) (applicable to Part A) and before vaccination at Visit 9 (Day 1B) (applicable to Part B).
5. Has a known hypersensitivity to any component of V116, PCV15, or PPSV23, including diphtheria toxoid.

6. Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of autoimmune disease (including but not limited to the autoimmune conditions outlined in the Investigator Trial File Binder for this study).
7. Has a coagulation disorder contraindicating intramuscular vaccinations.
8. *Has a recent febrile illness (defined as oral or tympanic temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$]; axillary or temporal temperature $\geq 99.4^{\circ}\text{F}$ [$\geq 37.4^{\circ}\text{C}$]; or rectal temperature $\geq 101.4^{\circ}\text{F}$ [$\geq 38.6^{\circ}\text{C}$]) or received antibiotic therapy for any acute illness occurring <72 hours before receipt of any study vaccine.
9. Has a known malignancy that is progressing or has required active treatment <3 years before enrollment. **Note:** Participants with basal cell and/or squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.

Prior/Concomitant Therapy

10. Had prior administration of PCV15 or PCV20.
11. Is expected to receive any pneumococcal vaccine during the study outside the protocol.
12. *Received systemic corticosteroids (prednisone equivalent of ≥ 20 mg/day) for ≥ 14 consecutive days and has not completed treatment ≥ 14 days before receipt of study vaccine at Visit 2 (Day 1) (applicable to Part A) and before receipt of study vaccine at Visit 9 (Day 1B) (applicable to Part B). **Note:** Physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.
13. Is currently receiving immunosuppressive therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
14. *Received any nonlive vaccine ≤ 14 days before receipt of any study vaccine or is scheduled to receive any nonlive vaccine ≤ 30 days after receipt of any study vaccine. **Exception:** Inactivated influenza vaccine and SARS-CoV-2 mRNA or SARS-CoV-2 protein subunit vaccine may be administered, but must be given ≥ 7 days before or ≥ 15 days after receipt of any study vaccine.
15. *Received any live virus vaccine ≤ 30 days before receipt of any study vaccine or is scheduled to receive any live virus vaccine ≤ 30 days after receipt of any study vaccine.
16. Received a blood transfusion or blood products, including immunoglobulins ≤ 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤ 30 days after receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion.

Prior/Concurrent Clinical Study Experience

17. Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 2 months of participating in this current study.

Diagnostic Assessments

Not applicable

Other Exclusions

18. In the opinion of the investigator, has a history of clinically relevant drug or alcohol use that would interfere with participation in protocol-specified activities.
19. Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound the results of the study, or interfere with the participant's participation for the full duration of the study.
20. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

For items with an asterisk (*), if the participant meets these exclusion criteria, the Day 1 Visit (Visit 2) and Day 1B Visit (Visit 9) may be rescheduled for a time when these criteria are not met.

Country-specific criteria are included in Appendix 7.

5.3 Lifestyle Considerations

No lifestyle restrictions are required.

5.4 Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study, but are not subsequently randomized in the study. A minimal set of screen-failure information is required to ensure transparent reporting of screen-failure participants to meet the CONSORT publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen-failure details, eligibility criteria, and any AEs or SAEs meeting reporting requirements as outlined in the data entry guidelines.

5.5 Participant Replacement Strategy

A participant who withdraws from the study will not be replaced.

6 STUDY INTERVENTION

Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.

Clinical supplies (V116, PCV15, PPSV23, placebo) will be packaged to support enrollment. Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.

6.1 Study Intervention(s) Administered

The study interventions to be used in this study are outlined in [Table 1](#).

Table 1 Study Interventions

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Admin.	Vaccination Regimen	Use	IMP or NIMP/ AxMP	Sourcing
V116	Experimental	Pneumococcal 21-valent conjugate vaccine	Biological/ Vaccine	Sterile Solution (Prefilled Syringe)	4 µg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B)	0.5 mL	IM	Single dose at Visit 2 (Day 1)	Test Product	IMP	Central
V116	Experimental	Placebo (sterile saline)	Biological/ Vaccine	Sterile Solution	N/A	0.5 mL	IM	Single dose at Visit 5 (Week 8)	Placebo	IMP	Central or local
V116	Experimental	Pneumococcal 15-valent conjugate vaccine	Biological/ Vaccine	Sterile Suspension (Prefilled Syringe)	2 µg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) and 4 µg of PnPs antigen 6B	0.5 mL	IM	Single dose at Visit 9 (Day 1B)	Test Product	IMP	Central or local
PCV15 + PPSV23	Active Comparator	Pneumococcal 15-valent conjugate vaccine	Biological/ Vaccine	Sterile Suspension (Prefilled Syringe)	2 µg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) and 4 µg of PnPs antigen 6B	0.5 mL	IM	Single dose at Visit 2 (Day 1)	Comparator	IMP	Central or local
PCV15 + PPSV23	Active Comparator	Pneumococcal vaccine, polyvalent (23-valent)	Biological/ Vaccine	Sterile Solution (Prefilled Syringe)	25 µg of each PnPs antigen (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)	0.5 mL	IM	Single dose at Visit 5 (Week 8)	Comparator	IMP	Central or local

Arm Name	Arm Type	Intervention Name	Intervention Type	Dose Formulation	Unit Dose Strength(s)	Dosage Level(s)	Route of Admin.	Vaccination Regimen	Use	IMP or NIMP/AxMP	Sourcing
<p>Admin.=administration; IM=intramuscular; IMP=investigational medicinal product; NIMP/AxMP=noninvestigational/auxiliary medicinal product; N/A=not applicable; PCV15=pneumococcal 15-valent conjugate vaccine (VAXNEUVANCE™); PnPs=pneumococcal polysaccharide; PPSV23=pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX™23); V116=pneumococcal 21-valent conjugate vaccine</p> <p>The classification of IMP and NIMP/AxMP in this table is based on guidance issued by the European Commission and applies to countries in the European Economic Area (EEA). Country differences with respect to the definition/classification of IMP and NIMP/AxMP may exist. In these circumstances, local legislation is followed.</p>											

All supplies indicated in [Table 1](#) will be provided per the “Sourcing” column depending on local country operational requirements. If local sourcing, every attempt should be made to source these supplies from a single lot/batch number where possible (eg, not applicable in the case where multiple lots or batches may be required due to the length of the study, etc).

Refer to Section 8.1.8 for details regarding administration of the study intervention.

6.1.1 Medical Devices

Drug-device combination product(s), which is legally marketed, provided for use in this study are: VAXNEUVANCE™ prefilled syringes and PNEUMOVAX™23 prefilled syringes. Refer to Section 8.4.8 and Appendix 4 for reporting events associated with these devices.

6.2 Preparation/Handling/Storage/Accountability

6.2.1 Dose Preparation

There are no specific calculations or evaluations required to be performed to administer the proper dose to each participant. The rationale for selection of doses to be used in this study is in Section 4.3.

Specific procedures that are required for dose preparation are outlined in the Investigator Trial File Binder.

As detailed in Section 6.3.3, study vaccine will be prepared by an unblinded member of the study-site staff in Part A of the study.

6.2.2 Handling, Storage, and Accountability

The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received, and any discrepancies are reported and resolved before use of the study intervention.

Only participants enrolled in the study may receive study intervention, and only authorized site staff may supply or administer study intervention. All study interventions must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.

The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).

For all study sites, the local country Sponsor personnel or designee will provide appropriate documentation that must be completed for drug accountability and return, or local discard and destruction if appropriate. Where local discard and destruction is appropriate, the

investigator is responsible for ensuring that a local discard/destruction procedure is documented.

The study site is responsible for recording the lot number, manufacturer, and expiry date for any locally purchased product (if applicable) as per local guidelines unless otherwise instructed by the Sponsor.

The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution, and usage of study interventions in accordance with the protocol and any applicable laws and regulations.

6.3 Measures to Minimize Bias: Randomization and Blinding

6.3.1 Intervention Assignment

Intervention randomization will occur centrally using an IRT system. There are 2 study intervention arms. Participants will be assigned randomly in a 1:1 ratio to receive either V116 + placebo or PCV15 + PPSV23 in Part A. Participants who received V116 in Part A will receive PCV15 in Part B.

6.3.2 Stratification

Intervention allocation/randomization will be stratified according to the following factors:

- Prior pneumococcal vaccination status:
 - PCV13 and PPSV23 naïve
 - Prior PCV13 only
 - Prior PPSV23 only or prior PCV13 and PPSV23

Approximately 50% of participants will be naïve to PCV13 and PPSV23.

- CD4+ T-cell count at Screening:
 - ≥ 50 to < 500 cells/ μ L
 - ≥ 500 cells/ μ L

Pneumococcal vaccine-naïve participants are defined as individuals ≥ 18 years of age without prior receipt of PCV13 and PPSV23. Pneumococcal vaccine-experienced participants are defined as individuals ≥ 18 years of age with prior receipt of ≥ 1 dose of either PCV13 and/or PPSV23.

Participants with prior receipt of pneumococcal vaccines during childhood will be handled as follows:

- Individuals who received PCV7 alone as part of their routine pediatric vaccination schedule will be eligible for enrolment and categorized as vaccine-naïve in this study.
- Individuals who received PCV13 as part of their routine pediatric schedule will not be eligible for this study as these individuals will be <18 years of age in 2022 (PCV13 was approved first in the US in 2010). Individuals with a history of receipt of PCV13 alone, PPSV23 alone, or PCV13 and PPSV23 as part of the sequential regimen during later childhood or adolescence due to an increased risk of pneumococcal disease and who are ≥18 years at the time of the study will be eligible and will be categorized as pneumococcal vaccine-experienced.
- Individuals who received PCV10 as part of their pediatric vaccination schedule will not be eligible for this study as these individuals will be <18 years of age at the time of study initiation.

6.3.3 Blinding

Part A

A double-blinding technique with in-house blinding will be used. V116, PCV15, PPSV23, and placebo will be prepared and/or dispensed in a blinded fashion by an unblinded pharmacist or qualified study-site personnel. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the clinical evaluation of the participants are unaware of the intervention assignments.

Because V116, PCV15, PPSV23, and placebo have different appearances, the unblinded pharmacist (or qualified study-site personnel) will be responsible for receiving, maintaining, preparing and/or dispensing, and administering these study vaccines (Section 8.1.8).

To avoid bias, contact between the unblinded study-site personnel and study participants is strictly prohibited for any study-related procedures/assessments other than administration of study vaccines. Blinded site personnel will be responsible for all other study procedures/assessments specified in Section 1.3.1.

An unblinded Clinical Research Associate will monitor vaccine accountability at the study site. All other Sponsor personnel or delegate(s) directly involved with the conduct of this study will remain blinded to the participant-level intervention assignment.

See Section 8.1.13 for a description of the method of unblinding a participant during the study should such action be warranted.

Part B

Part B of the study is open-label; therefore, the Sponsor, investigator, and participant will be aware that PCV15 is administered.

6.4 Study Intervention Compliance

Interruptions from the protocol-specified vaccination plan require consultation between the investigator and the Sponsor and written documentation of the collaborative decision on participant management.

6.5 Concomitant Therapy

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing study (Section 5.2). If there is a clinical indication for any medications or vaccinations specifically prohibited, discontinuation from study intervention may be required. The investigator should discuss any questions regarding this with the Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician. However, the decision to continue the participant on study intervention requires the mutual agreement of the investigator, the Sponsor, and the participant.

It is important to record the use of any analgesic or antipyretic medication that occurs on the day of vaccination on the eVRC and appropriate eCRF.

Listed below are specific restrictions for concomitant therapy or vaccination:

- Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
- Nonstudy vaccines may only be administered before or after the receipt of study vaccines according to the time frames specified in the Exclusion Criteria (Section 5.2).
- Receipt of systemic corticosteroids (prednisone equivalent ≥ 20 mg/day) for ≥ 14 consecutive days is prohibited from 14 days before each vaccination through 30 days following each vaccination. **Note:** Physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.

Any deviation from the above requires consultation between the investigator and the Sponsor and written documentation of the collaborative decision on participant management.

Use of prior and concomitant medications/vaccinations should be recorded as described in Section 8.1.5.

Country-specific requirements for concomitant therapy are included in Appendix 7.

6.5.1 Rescue Medications and Supportive Care

No rescue or supportive medications are specified for use in this study.

6.6 Dose Modification

No dose modification is allowed in this study.

6.7 Intervention After the End of the Study

There is no study-specified intervention after the end of the study.

6.8 Clinical Supplies Disclosure

Part A

Part A of the study is blinded but supplies are provided as open label; therefore, an unblinded pharmacist or qualified study-site personnel will be used to blind supplies. Study intervention identity (name, strength, or potency) is included in the label text; random code/disclosure envelopes or lists are not provided.

The emergency unblinding call center will use the intervention/randomization schedule for the study to unblind participants and to unmask study intervention identity. The emergency unblinding call center should only be used in cases of emergency (see Section 8.1.13). If the emergency unblinding call center is not available for a given site in this study, the central electronic intervention randomization system (IRT) should be used to unblind participants and to unmask study intervention identity. The Sponsor will not provide random code/disclosure envelopes or lists with the clinical supplies.

See Section 8.1.13 for a description of the method of unblinding a participant during the study, should such action be warranted.

Part B

Part B of the study is open-label; therefore, the participant, the study-site personnel, the Sponsor, and/or designee are not blinded. Study intervention (name, strength, or potency) is included in the label text; random code/disclosure envelopes or lists are not provided.

6.9 Standard Policies

Not applicable

7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT WITHDRAWAL

7.1 Discontinuation of Study Intervention

Discontinuation of study intervention does not represent withdrawal from the study.

As certain data on clinical events beyond study intervention discontinuation may be important to the study, they must be collected through the participant's last scheduled follow-up, even if the participant has discontinued study intervention. Therefore, all participants who discontinue study intervention before completion of the protocol-specified vaccination regimen will still continue to participate in the study as specified in Sections 1.3.1, 1.3.2, and 8.12.3.

Participants may discontinue study intervention at any time for any reason or be discontinued from the study intervention at the discretion of the investigator should any untoward effect occur. In addition, a participant may be discontinued from study intervention by the investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or for administrative and/or other safety reasons. Specific details regarding procedures to be performed at study intervention discontinuation are provided in Section 8.1.12 and Section 8.12.3.

A participant must be discontinued from study intervention, but continue to be monitored in the study, for any of the following reasons:

- The participant or participant's legally acceptable representative requests to discontinue study intervention.
- The participant has a medical condition or personal circumstance which, in the opinion of the investigator and/or Sponsor, placed the participant at unnecessary risk from continued administration of study intervention.
- The participant has a confirmed positive urine or serum pregnancy test before vaccination at Visit 5 (Week 8) in Part A and/or before vaccination at Visit 9 (Day 1B) in Part B.

7.2 Participant Withdrawal From the Study

A participant must be withdrawn from the study if the participant or participant's legally acceptable representative withdraws consent from the study.

If a participant withdraws from the study, they will no longer receive study intervention or be followed at scheduled protocol visits.

Specific details regarding procedures to be performed at the time of withdrawal from the study, as well as specific details regarding withdrawal from FBR, are outlined in Section 8.1.12. The procedures to be performed should a participant repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the participant are outlined in Section 7.3.

7.3 Lost to Follow-up

If a participant fails to return to the clinic for a required study visit and/or if the site is unable to contact the participant, the following procedures are to be performed:

- The site must attempt to contact the participant and reschedule the missed visit. If the participant is contacted, the participant should be counseled on the importance of maintaining the protocol-specified visit schedule.
- The investigator or designee must make every effort to regain contact with the participant at each missed visit (eg, telephone calls and/or a certified letter to the participant's last known mailing address or locally equivalent methods). These contact attempts should be documented in the participant's medical record.

- Note: A participant is not considered lost to follow-up until the last scheduled visit for the individual participant. The missing data for the participant will be managed via the prespecified statistical data handling and analysis guidelines.

8 STUDY ASSESSMENTS AND PROCEDURES

- Study procedures and their timing are summarized in the SoA.
- Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct.
- The investigator is responsible for ensuring that procedures are conducted by appropriately qualified (by education, training, and experience) staff. Delegation of study-site personnel responsibilities will be documented in the Investigator Trial File Binder (or equivalent).
- All study-related medical decisions must be made by an investigator who is a qualified physician.
- All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria. The investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.
- Procedures conducted as part of the participant's routine clinical management (eg, blood count) and obtained before signing of ICF may be used for screening or baseline purposes provided the procedure met the protocol-specified criteria and were performed within the time frame defined in the SoA.
- Additional evaluations/testing may be deemed necessary by the investigator and or the Sponsor for reasons related to participant safety. In some cases, such evaluation/testing may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations may require that additional informed consent be obtained from the participant. In these cases, such evaluations/testing will be performed in accordance with those regulations.

In Part A, the maximum amount of blood collected from each participant at each visit will not exceed 78.5 mL, and the total amount of blood collected over the duration of Part A will not exceed 246.5 mL (Table 2). For participants who enter Part B, a maximum of additional 196 mL blood will be collected (Table 3).

Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.

Table 2 Approximate Blood Volumes Drawn by Study Visit and by Sample Types for Part A

	Visit 1 (Screening)	Visit 2 (Day 1)	Visit 4 (Day 30)	Visit 7 (Week 12)
Parameter	Approximate Blood Volume (mL)			
Blood sample for HIV serology	4 mL	N/A	N/A	N/A
Blood sample for CD4+ T-cell count	2 mL	N/A	2 mL	2 mL
Blood sample for plasma HIV RNA testing	6 mL	N/A	6 mL	6 mL
Immunogenicity assessment	N/A	30 mL	30 mL	30 mL
DNA for FBR ^a	N/A	8.5 mL	N/A	N/A
Assay development ^a	N/A	40 mL	40 mL	40 mL
Expected total (mL)	12 mL	78.5 mL	78 mL	78 mL
DNA=deoxyribonucleic acid; FBR=future biomedical research; HIV=human immunodeficiency virus; N/A=not applicable; RNA=ribonucleic acid ^a Samples for FBR and assay development will only be obtained from participants who provide separate consent for collection of these optional samples.				

Table 3 Approximate Blood Volumes Drawn by Study Visit and by Sample Types for Part B

	Visit 9 (Day 1B)	Visit 11 (Day 30B)
Parameter	Approximate Blood Volume (mL)	
Blood sample for CD4+ T-cell count	2 mL	2 mL
Blood sample for plasma HIV RNA testing	6 mL	6 mL
Immunogenicity assessment ^a	50 mL	50 mL
Assay development ^b	40 mL	40 mL
Expected total (mL)	98 mL	98 mL
HIV=human immunodeficiency virus; MOPA=Multiplexed Opsonophagocytic Assay; Pn ECL=pneumococcal electrochemiluminescence; RNA=ribonucleic acid ^a 30 mL blood for V116 MOPA and Pn ECL assay; 20 mL blood for PCV15 MOPA and Pn ECL assay ^b Samples for assay development will only be obtained from participants who provide separate consent for collection of these optional samples.		

8.1 Administrative and General Procedures

8.1.1 Informed Consent

The investigator or medically qualified designee (consistent with local requirements) must obtain documented informed consent from each potential participant (or their legally acceptable representative) prior to participating in this clinical study or FBR. If there are changes to the participant's status during the study (eg, health or age of majority requirements), the investigator or medically qualified designee must ensure the appropriate documented informed consent is in place.

8.1.1.1 General Informed Consent

Informed consent given by the participant or their legally acceptable representative must be documented on a consent form. The form must include the study protocol number, study protocol title, dated signature, and agreement of the participant (or his/her legally acceptable representative) and of the person conducting the consent discussion.

A copy of the signed and dated informed consent form should be given to the participant (or their legally acceptable representative) before participation in the study.

The initial ICF, any subsequent revised ICF, and any written information provided to the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The participant or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the participant's willingness to continue participation in the study. The communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participant's or the participant's legally acceptable representative's dated signature.

Specifics about the study and the study population are to be included in the study informed consent form.

Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and Sponsor requirements.

8.1.1.2 Consent and Collection of Specimens for Future Biomedical Research

The investigator or medically qualified designee will explain the FBR consent to the participant, or the participant's legally acceptable representative, answer all of his/her questions, and obtain documented informed consent before performing any procedure related to FBR. A copy of the informed consent will be given to the participant before performing any procedure related to FBR.

8.1.1.3 Consent and Collection of Specimens for Optional Assay Development

The investigator or medically qualified designee will explain the consent for the optional assay development blood samples to the participant, answer all of their questions, and obtain

documented informed consent before performing any procedure related to the optional assay development blood samples collection. A copy of the informed consent will be given to the participant.

8.1.2 Inclusion/Exclusion Criteria

All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified physician, to ensure that the participant qualifies for the study.

8.1.3 Participant Identification Card

All participants will be given a participant identification card identifying them as participants in a research study. The card will contain study-site contact information (including direct telephone numbers) to be used in the event of an emergency. The investigator or qualified designee will provide the participant with a participant identification card immediately after the participant provides documented informed consent. At the time of intervention randomization, site personnel will add the treatment/randomization number to the participant identification card.

The participant ID card also contains contact information for the emergency unblinding call center so that a health care provider can obtain information about study intervention in emergency situations where the investigator is not available.

8.1.4 Medical History

A medical history will be obtained by the investigator or qualified designee. The participant's relevant medical history for the 5 years before Day 1 will be obtained to ensure that the participant satisfies the inclusion and exclusion criteria of the study. History of tobacco use will be collected for all participants.

8.1.5 Prior and Concomitant Medications Review

8.1.5.1 Prior Medications

The investigator or qualified designee will review prior medications and vaccinations taken by the participant before Visit 1 (Screening), Visit 2 (Day 1), and Visit 9 (Day 1B) to ensure the participant satisfies the inclusion and exclusion criteria.

The following must be recorded in the participant's source documents and on the appropriate eCRF before the first vaccination in Part A and before vaccination in Part B:

- Prior medications and vaccinations taken by the participant within 30 days before study vaccination at Visit 2 and Visit 9
- Receipt of any pneumococcal vaccine and current ART regardless of timing prior to Visit 2 and Visit 9

- Any analgesic or antipyretic medication taken on the day of vaccination before vaccination at Visit 2 and Visit 9

8.1.5.2 Concomitant Medications

The investigator or qualified designee will record vaccinations and medications, if any, taken by the participant during the study.

Any analgesic or antipyretic medication taken must be recorded on the eVRC and appropriate eCRF.

The participant will use their eVRC (Section 8.1.9) to record new and/or concomitant medications taken and nonstudy vaccines received from the day of each vaccination through 30 days postvaccination.

8.1.6 Assignment of Screening Number

All consented participants will be given a unique screening number that will be used to identify the participant for all procedures that occur before randomization. Each participant will be assigned only 1 screening number. Screening numbers must not be reused for different participants.

Any participant who is screened multiple times will retain the original screening number assigned at the initial Screening Visit. Specific details on the screening/rescreening visit requirements are in Section 8.12.1.

8.1.7 Assignment of Treatment/Randomization Number

All eligible participants will be randomly allocated and will receive a treatment/randomization number. The treatment/randomization number identifies the participant for all procedures occurring after treatment randomization. Once a treatment/randomization number is assigned to a participant, it can never be reassigned to another participant.

A single participant cannot be assigned more than 1 treatment/randomization number.

8.1.8 Study Intervention Administration

For Part A only: Unblinded study personnel will prepare and administer study vaccines (Section 6.3.3). The unblinded study personnel who administer study vaccines should not have contact with participants for any other study-related procedures/assessments.

Blinded site personnel will not be present in the examination room when study vaccines are administered.

Study vaccines should be prepared and administered by appropriately qualified members of the study personnel (eg, physician, nurse, physician's assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by local/state, country, and institutional

guidance. Procedures for handling, preparing, and administering study vaccines are provided in the Investigator Trial File Binder.

Study vaccine will be administered as a single IM injection, preferably in the deltoid region of the participant's arm, according to the schedule specified in Sections 1.3.1 and 1.3.2. Adequate treatment provision, including epinephrine and equipment for maintaining an airway, should be available for immediate use should an anaphylactic or anaphylactoid reaction occur [Centers for Disease Control and Prevention 2015].

8.1.8.1 Timing of Dose Administration

Study vaccines will be administered as indicated in Sections 1.3.1 and 1.3.2. Vaccinations may be administered at any time of day and without regard to timing of meals.

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions (Section 8.3.5). This observation must be performed by blinded site personnel for Part A (Section 6.3.3).

Participants must not have a fever reported within 72 hours before vaccination (Sections 1.3.1, 1.3.2, and 8.3.4).

Administration of pregnancy tests (if applicable) must be performed before vaccine administration.

The collection of blood samples should be performed before vaccine administration.

8.1.9 Electronic Vaccination Report Card

The eVRC is structured as recommended in the final FDA Patient-reported Outcome Guidance [U.S. Food and Drug Administration 2009].

The participant will use the eVRC to record body temperature (Section 8.3.4), solicited injection-site AEs, and solicited systemic AEs (Section 8.4.9.1). Unsolicited AEs (Section 8.4.9.2), concomitant medications (including use of any analgesic or antipyretic medication), and nonstudy vaccinations (Section 8.1.5.2) will also be reported. Participants will be provided an electronic device or have their own electronic device configured, if compatible, to complete the eVRC.

The investigator or delegate will review the data captured on the eVRC with the participant as indicated in Sections 1.3.1 and 1.3.2. Any differences between data reported by the participant on the eVRC and data entered into the clinical database must be clearly explained in the participant's source documents.

8.1.10 Telephone Contact Questionnaire

For Part A, site personnel will contact the participant (or the participant's legally acceptable representative, as applicable) as indicated in Section 1.3.1 to collect additional information based on a Telephone Contact Questionnaire provided by the Sponsor. Data to be reported

from this discussion will include SAEs and/or any updates to previously reported safety information.

8.1.11 Confirmation of Eligibility in Part B

Upon database lock and unblinding of Part A, site personnel and participants will be notified of intervention assignment received in Part A.

Participants who received V116 alone or V116 + placebo in Part A (regardless of intervention group assigned) are eligible to return to the site for participation in Part B.

All exclusion criteria in Section 5.2 will be reviewed by the investigator at Visit 9 (Day 1B) before receipt of study vaccine to ensure that the participant qualifies for Part B of the study.

8.1.12 Discontinuation and Withdrawal

Participants who discontinue study intervention before completion of the vaccination regimen should be encouraged to continue to be followed for all remaining study visits as outlined in the SoA and Section 8.12.3.

Participants who withdraw from the study should be encouraged to complete all applicable activities scheduled for the last study visit in Part A or the final study visit in Part B as applicable at the time of withdrawal. Any AEs that are present at the time of withdrawal should be followed in accordance with the safety requirements outlined in Section 8.4.

8.1.12.1 Withdrawal From Future Biomedical Research

Participants may withdraw their consent for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's consent for FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the investigator to inform the participant of completion of withdrawal. Any analyses in progress at the time of request for withdrawal or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for specimen withdrawal cannot be processed.

8.1.13 Participant Blinding/Unblinding

Part A

STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY EFFORT SHOULD BE MADE NOT TO UNBLIND.

For emergency situations where the investigator or medically qualified designee (consistent with local requirements) needs to identify the intervention used by a participant and/or the dosage administered, he/she will contact the emergency unblinding call center by telephone and make a request for emergency unblinding. As requested by the investigator or medically qualified designee, the emergency unblinding call center will provide the information to him/her promptly and report unblinding to the Sponsor. Before contacting the emergency unblinding call center to request unblinding of a participant's intervention assignment, the investigator who is a qualified physician should make reasonable attempts to enter the intensity grade of the AEs observed, the relation to study intervention, the reason thereof, etc, in the medical record. If it is not possible to record this assessment in the medical record before the unblinding, the unblinding should not be delayed.

If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and person performing the unblinding) must be documented promptly, and the Sponsor Clinical Director notified as soon as possible.

Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be provided to the participant.

Participants whose treatment assignment has been unblinded by the investigator or medically qualified designee and/or nonstudy treating physician should continue to be monitored in the study. Participants may receive study intervention at Visit 5 (Week 8) after a benefit/risk assessment and consultation between the investigator/delegate and Sponsor.

Additionally, the investigator or medically qualified designee must go into the IRT system and perform the unblind in the IRT system to update drug disposition. If the emergency unblinding call center is not available for a given site in this study, the IRT system should be used for emergency unblinding if this is required for participant safety.

Part B

Part B of the study is open-label; there is no blinding. The emergency unblinding call center will be available so that a health care provider can obtain information about study intervention in emergency situations where the investigator is not available.

8.1.14 Calibration of Equipment

The investigator or qualified designee has the responsibility to ensure that any device or instrument used for a clinical evaluation/test during a clinical study that provides information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. Documentation of equipment calibration must be retained as source documentation at the study site.

8.2 Immunogenicity Assessments

Sera from participants will be used to measure vaccine-induced OPA and IgG responses. These endpoints will be tested for all immunogenicity blood draws specified in Sections 1.3.1 and 1.3.2. Blood collection, storage, and shipment instructions for serum samples will be provided in the operations/laboratory manual.

The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for phagocytosis is an important mechanism by which antibodies to polysaccharides protect against disease in vivo. The OPA assay is a useful tool for assessing the protective function of serotype-specific antibodies and, therefore, the immunogenicity of pneumococcal vaccine formulations.

Serotype-specific IgG will be measured using the Pn ECL assay to assess the concentration of binding antibodies to capsular polysaccharide of *S pneumoniae*.

After completion of immunogenicity testing to evaluate the study objectives, serum samples will be stored to conduct any additional study-related testing as requested by regulatory agencies or the Sponsor. For participants who provide optional consent for FBR, leftover sera from the study may be used for other purposes, such as the development and/or validation of pneumococcal assays after completion of all study-related immunogenicity testing.

8.2.1 Multiplex Opsonophagocytic Assay

The MOPA is an antibody-mediated killing assay that measures the ability of human serum to kill *S pneumoniae* serotypes with the help of complement and phagocytic effector cells [Burton, Robert L. and Nahm, Moon H. 2006]. The ability of the assay to simultaneously test 4 serotypes at a time reduces the amount of serum needed for testing. The assay readout is the opsonization index, which is the reciprocal of the highest dilution that gives $\geq 50\%$ bacterial killing, as determined by comparison to assay background controls. The MOPA for V116 and PCV15 have been validated for various performance parameters of the assay including precision, ruggedness, relative accuracy/dilutional linearity, and the limit of detection of the assay.

MOPA for V116

The Sponsor has developed and optimized the MOPA in a high-throughput microcolony platform, which not only covers all 21 serotypes in V116, but also includes serotypes 6C and

15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured.

MOPA for PCV15

The Sponsor has also developed and optimized the MOPA in a high-throughput microcolony platform, which covers all 15 serotypes in PCV15.

8.2.2 Pneumococcal Electrochemiluminescence Assay

The Sponsor has developed, optimized, and validated a multiplex, ECL-based detection method for the quantitation of IgG serotype-specific antibodies. The ECL assay is based on the Meso-Scale Discovery technology, which employs disposable multispot microtiter plates. Briefly, PnPs are bound to the surface of 96-well 10 plex carbon microplates, and serum containing purported anti-PnPs antibodies is added. The anti-PnPs antibodies bind to the coated plates and form an antibody-antigen complex. The bound antibody-antigen complex can be detected using a ruthenium labeled anti-human IgG. Plates are read by measure of the chemiluminescent signal emitted from the ruthenium tag upon electrochemical stimulation initiated at the electrode surfaces of the microplates. ^{CCI}

Assay validation studies showed excellent performance operating characteristics for precision (intra- and interassay), dilutability, ruggedness (to different plate lots and analysts), relative accuracy, and specificity.

ECL for V116

This multiplexed ECL assay not only detects all 21 serotypes contained in V116 but also detects serotypes 6C and 15B so that antibodies induced by vaccine serotypes 6A and 15C but cross-reactive to serotypes 6C and 15B, respectively, can be measured.

ECL for PCV15

The ECL assay for PCV15 detects all 15 serotypes contained in PCV15.

8.3 Safety Assessments

Details regarding specific safety procedures/assessments to be performed in this study are provided below.

Planned time points for all safety assessments are provided in the SoA.

8.3.1 Physical Examinations

A complete physical examination and a brief directed physical examination will be conducted by an investigator or medically qualified designee (consistent with local requirements) per institutional standard before vaccination as indicated in Sections 1.3.1 and 1.3.2.

Findings related to the physical examinations should be documented in the source documents. Investigators should pay special attention to clinical signs related to previous serious illnesses.

8.3.2 Pregnancy Testing

A pregnancy test consistent with local requirements (sensitive to at least 25 IU hCG) must be performed before vaccination in WOCBP as indicated in Sections 1.3.1 and 1.3.2.

Urine or serum tests can be used and results must be negative before vaccination can occur. A detailed definition of WOCBP is provided in Appendix 5.

- Pregnancy testing:
 - Pregnancy testing requirements for study inclusion are described in Section 5.1.
 - Additional serum or urine pregnancy tests may be performed, as determined necessary by the investigator or required by local regulation, to establish the absence of pregnancy at any time during the subject's participation in the study.

8.3.3 HIV Serology, CD4+ T-cell Count, and Plasma HIV RNA Testing

Serum for assessment of HIV serology and a blood sample for CD4+ T-cell count and plasma HIV RNA testing will be collected at Visit 1 (Screening) to confirm inclusion criteria related to HIV infection. Additionally, blood samples for CD4+ T-cell count and plasma HIV RNA testing will be collected as indicated in Sections 1.3.1 and 1.3.2.

8.3.4 Body Temperature Measurement

Each participant's body temperature must be taken by study-site staff before vaccination as described in Sections 1.3.1 and 1.3.2. The prevaccination temperature should be documented in the participant's source documents. Participants who have febrile illness (defined as oral or tympanic temperature $\geq 100.4^{\circ}\text{F}$ [$\geq 38.0^{\circ}\text{C}$]; axillary or temporal temperature $\geq 99.4^{\circ}\text{F}$ [$\geq 37.4^{\circ}\text{C}$]) <72 hours before vaccination must be rescheduled.

Participants will also record oral body temperature measurements using the eVRC (Section 8.1.9) from Day 1 through Day 5 after each vaccination.

8.3.5 Postvaccination Observation Period

All participants will be observed for at least 30 minutes after vaccination for any immediate reactions. If any immediate AEs are observed during this period, the time at which the event occurred within this timeframe, as well as the event itself, any concomitant medications that were administered, and resolution of the event must be recorded on the appropriate eCRF.

8.3.6 Clinical Safety Laboratory Assessments

Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for the timing and frequency.

- The investigator or medically qualified designee (consistent with local requirements) must review the laboratory report, document this review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
- All protocol-required laboratory assessments, as defined in Appendix 2, must be conducted in accordance with the laboratory manual and the SoA.
- If laboratory values from nonprotocol-specified laboratory assessments performed at the institution's local laboratory require a change in study participant management or are considered clinically significant by the investigator (eg, SAE or AE or dose modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
- For any laboratory tests with values considered clinically significantly abnormal during participation in the study or within 30 to 44 days after the last dose of study intervention, every attempt should be made to perform repeat assessments until the values return to normal or baseline or if a new baseline is established as determined by the investigator.

8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety Events

The definitions of an AE or SAE, as well as the method of recording, evaluating, and assessing causality of AE and SAE and the procedures for completing and transmitting AE, SAE, and other reportable safety event reports can be found in Appendix 3.

Adverse events, SAEs, and other reportable safety events will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative).

The investigator and any designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE as well as other reportable safety events. Investigators need to document if an SAE was associated with a medication error, misuse, or abuse. Investigators remain responsible for following up AEs, SAEs, and other reportable safety events for outcome according to Section 8.4.3.

The investigator, who is a qualified physician, will assess events that meet the definition of an AE or SAE as well as other reportable safety events with respect to seriousness, intensity/toxicity and causality.

8.4.1 Time Period and Frequency for Collecting AE, SAE, and Other Reportable Safety Event Information

All AEs, SAEs, and other reportable safety events that occur after the participant provides documented informed consent, but before randomization, must be reported by the investigator if they cause the participant to be excluded from the study, or are the result of a protocol-specified intervention, including, but not limited to washout or discontinuation of usual therapy, diet, placebo, or a procedure.

All nonserious AEs and other reportable safety events (excluding pregnancy and lactation exposure) must be reported by the investigator from the day of randomization through 30 days after the first vaccination and from the time of each subsequent vaccination through 30 days postvaccination.

All pregnancies and lactation exposure during breastfeeding must be reported by the investigator 1) from the day of randomization through 6 weeks after the final vaccination in Part A, and 2) from the day of vaccination through 14 days postvaccination in Part B.

All SAEs, regardless of whether related to the study intervention, must be reported by the investigator through 6 months of initial vaccination (Day 1) in Part A and through 30 days postvaccination for participants in Part B.

In addition, any SAE brought to the attention of the investigator at any time outside the periods specified in the previous paragraph must be reported immediately to the Sponsor if the event is either:

- A death that occurs before the participant completes the study.

OR

- An SAE that is considered by an investigator, who is a qualified physician, to be vaccine related.

Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a participant has been discharged from the study, and the investigator considers the event to be reasonably related to the study intervention or study participation, the investigator must promptly notify the Sponsor.

All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and reported to the Sponsor or designee within the time frames as indicated in [Table 4](#).

Exception: A positive pregnancy test at the time of initial screening is not a reportable event unless the participant has received study intervention.

Table 4 Reporting Time Periods and Time Frames for Adverse Events and Other Reportable Safety Events

Type of Event	Reporting Time Period: Consent to Randomization/ Allocation	Reporting Time Period: Randomization/ Allocation through Protocol-specified Follow-up Period	Reporting Time Period: After the Protocol- specified Follow- up Period	Time Frame to Report Event and Follow-up Information to Sponsor:
NSAE	Report if: - due to protocol- specified intervention - causes exclusion - participant is receiving placebo run-in or other run-in treatment	Report all	Not required	Per data entry guidelines
SAE	Report if: - due to protocol- specified intervention - causes exclusion - participant is receiving placebo run-in or other run-in treatment	Report all	Report if: - drug/vaccine related. - any death until participant completion of study (Follow ongoing to outcome)	Within 24 hours of learning of event
Pregnancy/ Lactation Exposure	Report if: - participant has been exposed to any protocol- specified intervention (eg, procedure, washout or run-in treatment including placebo run-in) Exception: A positive pregnancy test at the time of initial screening is not a reportable event.	Report all	Previously reported – Follow to completion/ termination; report outcome	Within 24 hours of learning of event
ECI (require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - Potential DILI - Require regulatory reporting	Not required	Within 24 hours of learning of event
ECI (do not require regulatory reporting)	Report if: - due to intervention - causes exclusion	Report - non-DILI ECIs and those not requiring regulatory reporting	Not required	Within 5 calendar days of learning of event
Cancer	Report if: - due to intervention - causes exclusion	Report all	Not required	Within 5 calendar days of learning of event (unless serious)
Overdose	Report if: - receiving placebo run-in or other run-in medication	Report all	Not required	Within 5 calendar days of learning of event

DILI=drug-induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse event.

8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events

Care will be taken not to introduce bias when detecting AEs and/or SAEs and other reportable safety events. Open-ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrence.

8.4.3 Follow-up of AE, SAE, and Other Reportable Safety Event Information

After the initial AE/SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events, including pregnancy and exposure during breastfeeding, ECIs, cancer, and overdose will be followed until resolution, stabilization, until the event is otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In addition, the investigator will make every attempt to follow all nonserious AEs that occur in randomized participants for outcome. Further information on follow-up procedures is given in Appendix 3.

8.4.4 Regulatory Reporting Requirements for SAE

Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.

The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country-specific regulatory requirements and global laws and regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.

Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAE) from the Sponsor will file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.

8.4.5 Pregnancy and Exposure During Breastfeeding

Although pregnancy and infant exposure during breastfeeding are not considered AEs, any pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to the investigator or their designee) that occurs during the study are reportable to the Sponsor.

All reported pregnancies must be followed to the completion/termination of the pregnancy.

Any pregnancy complication will be reported as an AE or SAE.

The medical reason (example: maternal health or fetal disease) for an elective termination of a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born with severe abnormalities/congenital anomalies that leads to an elective termination of a pregnancy will be reported as an SAE for the fetus.

Pregnancy outcomes of ectopic pregnancy, spontaneous abortion, missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.

8.4.6 Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs or SAEs

Not applicable for this study.

8.4.7 Events of Clinical Interest

There are no ECIs for this study.

8.4.8 Medical Device and Drug-device Combination Products - PQCs/Malfunctions

The method of documenting and reporting of such events (Complaints associated with medical devices including PQCs/malfunctions) will occur as below and in Appendix 4.

To fulfill regulatory reporting obligations worldwide, medical device information associated with AEs will be collected and reported to the Sponsor in the same time frame as AEs per Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines.

PQCs/malfunctions including those that involve a participant or any user/associated person must be reported to the Sponsor. Sponsor shall review reported events by the investigator to fulfill the legal responsibility of notifying appropriate regulatory authorities and other entities about certain safety information relating to medical devices and drug-device combination products being used in clinical studies.

The investigator is responsible for ensuring that follow-up includes any supplemental investigations as indicated to elucidate the nature and/or causality between the AE and the medical device or device constituent of combination product.

8.4.9 Adverse Events on the VRC

Participants will use an eVRC to report solicited and unsolicited AEs.

The definitions of solicited and unsolicited AEs can be found in Appendix 3.

8.4.9.1 Solicited Adverse Event

Solicited AEs for this study are summarized in [Table 5](#).

Table 5 Solicited Adverse Events

Type of Solicited Adverse Event	Predefined Solicited Adverse Events (Preferred Term)	Solicited Time Period
Injection site	<ul style="list-style-type: none">• Injection-site pain/tenderness (injection-site pain)• Injection-site redness (injection-site erythema)• Injection-site swelling (injection-site swelling)	Day 1 through Day 5 postvaccination
Systemic	<ul style="list-style-type: none">• Headache (headache)• Muscle aches all over body (myalgia)• Tiredness (fatigue)	Day 1 through Day 5 postvaccination

8.4.9.2 Unsolicited Adverse Events

Unsolicited AEs for this study are events that are 1) not predefined in [Table 5](#), or 2) predefined in [Table 5](#) but reported at any time outside the solicited time period.

8.5 Treatment of Overdose

In this study, an overdose is the administration of more than 1 dose of any individual study vaccine in any 24-hour period.

No specific information is available on the treatment of overdose.

8.6 Pharmacokinetics

PK parameters will not be evaluated in this study.

8.7 Pharmacodynamics

Pharmacodynamic parameters will not be evaluated in this study.

8.8 Biomarkers

Biomarkers are not evaluated in this study.

8.9 Future Biomedical Research Sample Collection

If the participant provides documented informed consent for FBR, the following specimens will be obtained as part of FBR:

- DNA for future research
- Leftover study serum after completion of immunogenicity testing stored for future research

8.10 Optional Assay Development Blood Sample Collection

If the participant provides documented informed consent for the optional assay development blood samples, these additional blood samples will be obtained as indicated in Sections 1.3.1 and 1.3.2. These blood samples will be used to support future development work on improving bioanalytical measurements, which requires high-volume single-donor samples to monitor performance of the assay over time.

Sample collection, storage, and shipment instructions for the optional assay development blood samples will be provided in the operations/laboratory manual.

8.11 Medical Resource Utilization and Health Economics

Medical Resource Utilization and Health Economics are not evaluated in this study.

8.12 Visit Requirements

Visit requirements are outlined in Sections 1.3.1 and 1.3.2. Specific procedure-related details are provided in Section 8.

8.12.1 Screening

Screening procedures will be conducted at Visit 1 as outlined in Section 1.3.1. Potential participants will be evaluated to determine that they fulfill the entry requirements as set forth in Section 5.

8.12.2 Treatment Period/Vaccination Visit

Requirements during the treatment period are outlined in Sections 1.3.1 and 1.3.2.

If Visit 2 (Day 1) and/or Visit 9 (Day 1B) are rescheduled (see Section 5.2), a pregnancy test (if applicable), a body temperature measurement, and a review of inclusion/exclusion criteria, prior medications/vaccinations, and medical history (if applicable), must be repeated before vaccination.

8.12.3 Participants Discontinued From Study Intervention but Continuing to be Monitored in the Study

A participant who discontinues from study intervention will continue to participate in protocol-specified activities as outlined in Sections 1.3.1 and 1.3.2, including blood draws for immunogenicity testing and AE-monitoring activities, as long as the participant does not withdraw consent.

9 STATISTICAL ANALYSIS PLAN

This section describes the statistical analysis strategy and procedures for the study. Changes to the analyses made after the protocol has been finalized, but prior to unblinding, will be

documented in an sSAP and referenced in the CSR for the study. Post hoc exploratory analyses will be clearly identified in the CSR.

9.1 Statistical Analysis Plan Summary

Key elements of the Statistical Analysis Plan are summarized below; the comprehensive plan is provided in Sections 9.2 through 9.12.

Study Design Overview	A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV
Treatment Assignment	Participants will be randomly assigned in a 1:1 ratio to receive V116 + placebo or PCV15 + PPSV23 in Part A. Randomization will be stratified by prior pneumococcal vaccination status (PCV13 and PPSV23 naïve; prior PCV13 only; prior PPSV23 only or prior PCV13 and PPSV23) and by CD4+ T-cell count at Screening (≥ 50 to < 500 cells/ μ L; ≥ 500 cells/ μ L) as described in Section 6.3.2. Participants who received V116 in Part A will receive PCV15 in Part B.
Analysis Populations	Immunogenicity: PP population Safety: APaT population
Primary Endpoint(s)	Part A Immunogenicity: <ul style="list-style-type: none"> Serotype-specific OPA GMTs postvaccination with V116 (30 days postvaccination [Day 30]) or PCV15 + PPSV23 (30 days postvaccination with the final dose in the regimen [Week 12]) Safety: <ul style="list-style-type: none"> Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, tenderness/pain) from Day 1 through Day 5 postvaccination Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, tiredness/fatigue) from Day 1 through Day 5 postvaccination Proportion of participants with vaccine-related SAEs from Day 1 through the duration of participation in Part A
Key Secondary Endpoints	Part A <ul style="list-style-type: none"> Serotype-specific IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)
Statistical Methods for Key Immunogenicity Analyses	Immunogenicity analyses will be conducted separately for each serotype in V116 within each vaccination group. To address the primary immunogenicity objective, evaluation of the OPA GMTs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12) will include descriptive summaries and within-group 95% CIs for each vaccination group.
Statistical Methods for Key Safety Analyses	For the overall safety evaluation, safety parameters will be summarized via descriptive statistics. For select safety parameters, point estimates and within-group 95% CIs will be provided.

Interim Analyses	<u>Part A and Part B</u> To support the periodic review of safety and tolerability data across the adult V116 Phase 3 program, an external unblinded statistician will provide unblinded interim safety summaries to an independent external DMC for their review. Unblinded immunogenicity data will be made available to the DMC upon request to enable a benefit-risk assessment.
Multiplicity	No multiplicity adjustment is planned as there is no hypothesis testing.
Sample Size and Power	This study will randomize approximately 150 participants into the V116 + placebo group and 150 participants into the PCV15 + PPSV23 group. It is assumed that 135 participants per vaccination group (90% evaluability rate) will be evaluable for PP immunogenicity analyses. There are no hypotheses to be evaluated, but Section 9.9.1 provides information about the expected variability of the OPA GMTs given the sample size.

9.2 Responsibility for Analyses/In-house Blinding

The statistical analysis of the data obtained from this study will be the responsibility of the Clinical Biostatistics department of the Sponsor.

Part A of this study will be conducted as a double-blind study under in-house blinding procedures. The official, final database in Part A will not be unblinded until medical/scientific review has been performed, protocol deviations have been identified, and data in Part A have been declared final and complete. Part B of the study will be open-label.

The Clinical Biostatistics department will generate the randomized allocation schedule(s) for study intervention assignment. Randomization will be implemented using an IRT system.

Blinding issues related to the planned interim analyses are described in Section 9.7.

9.3 Hypotheses/Estimation

Objectives of the study are stated in Section 3. This is an estimation study and no hypothesis testing will be performed.

9.4 Analysis Endpoints

Immunogenicity and safety analysis endpoints that will be summarized are listed below.

9.4.1 Immunogenicity Endpoints

In Part A and Part B, immune responses will be measured for each of the serotypes contained in V116: the 6 serotypes in common with PCV15 (3, 6A, 7F, 19A, 22F, and 33F); 7 additional serotypes in common with PPSV23 but not included in PCV15 (8, 9N, 10A, 11A, 12F, 17F, and 20); 8 unique serotypes in V116 (15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B); and 2 cross-reactive serotypes (6C and 15B).

In Part B, immune responses will also be measured for the 9 serotypes contained in PCV15 but not in V116 (1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F).

Part A

The primary immunogenicity endpoint includes:

- Serotype-specific OPA GMTs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)
 - 13 serotypes common between V116 and PCV15 + PPSV23
 - 8 serotypes unique to V116

The secondary immunogenicity endpoints include:

- Serotype-specific IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)
 - 13 serotypes common between V116 and PCV15 + PPSV23
 - 8 serotypes unique to V116
- Serotype-specific GMFR and proportion of participants with a ≥ 4 -fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12) for both OPA and IgG responses
 - 13 serotypes common between V116 and PCV15 + PPSV23
 - 8 serotypes unique to V116

The exploratory immunogenicity endpoints include:

- Serotype-specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)
 - 13 serotypes common between V116 and PCV15 + PPSV23
 - 8 serotypes unique to V116
- Serotype-specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) or PCV15 (Day 30)
 - 6 serotypes common between V116 and PCV15
 - 15 serotypes unique to V116

- Serotype-specific GMFR and proportion of participants with a ≥ 4 -fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) or PCV15 (Day 30) for both OPA and IgG responses
 - 6 serotypes common between V116 and PCV15
 - 15 serotypes unique to V116
- Summaries of the cross-reactive immune responses to serotypes within a serogroup using serotype-specific OPA and IgG responses

Part B

The exploratory immunogenicity endpoints include:

- Serotype-specific OPA GMTs and IgG GMCs postvaccination with PCV15 (Day 30B) for participants administered V116 in Part A
 - 6 serotypes common between V116 and PCV15
 - 15 serotypes unique to V116
 - 9 serotypes included in PCV15 but not in V116
- GMFR and proportion of participants with a ≥ 4 -fold rise from baseline (Day 1B) to postvaccination with PCV15 (Day 30B) for participants administered V116 in Part A for both OPA and IgG responses
 - 6 serotypes common between V116 and PCV15
 - 15 serotypes unique to V116
 - 9 serotypes included in PCV15 but not in V116

9.4.2 Safety Endpoints

Part A

The safety endpoints for overall safety assessment that address the primary safety objective include:

- Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1 through Day 5 postvaccination
- Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1 through Day 5 postvaccination

- Proportion of participants with vaccine-related SAEs from Day 1 through the duration of participation in Part A

Additional safety endpoints for overall safety assessment include:

- Proportion of participants with the broad AE categories consisting of any AE, any unsolicited AEs, and any vaccine-related AE from Day 1 through Day 30 postvaccination
- Proportion of participants with the broad AE categories consisting of any SAE, any vaccine-related SAE, discontinuation due to an AE, and death from Day 1 through the duration of participation in Part A
- Proportion of participants with maximum temperature measurements meeting the Brighton Collaboration cut points from Day 1 through Day 5 postvaccination

Part B

The safety endpoints for overall safety assessment that address the secondary safety objective include:

- Proportion of participants with solicited injection-site AEs (redness/erythema, swelling, and tenderness/pain) from Day 1B through Day 5B after PCV15 vaccination
- Proportion of participants with solicited systemic AEs (muscle aches all over body/myalgia, headache, and tiredness/fatigue) from Day 1B through Day 5B after PCV15 vaccination
- Proportion of participants with vaccine-related SAEs from Day 1B through the duration of participation in Part B

Additional safety endpoints for overall safety assessment include:

- Proportion of participants with the broad AE categories consisting of any AE, any unsolicited AEs, and any vaccine-related AE from Day 1B through Day 30B after PCV15 vaccination
- Proportion of participants with the broad AE categories consisting of any SAE, any vaccine-related SAE, discontinuation due to an AE, and death from Day 1B through the duration of participation in Part B
- Proportion of participants with maximum temperature measurements meeting the Brighton Collaboration cut points from Day 1B through Day 5B after PCV15 vaccination

9.5 Analysis Populations

9.5.1 Immunogenicity Analysis Populations

The PP population will serve as the primary population for the analysis of immunogenicity data in this study.

Part A

The PP population consists of all randomized participants without deviations from the protocol that may substantially affect the results of the immunogenicity endpoints. Potential deviations that may result in the exclusion of a participant from the PP population for all immunogenicity analyses include:

- Failure to receive study vaccine at Visit 2 (Day 1)
- Failure to receive correct clinical material as per randomization schedule
- Receipt of a prohibited medication or prohibited vaccine prior to study vaccination

Additional potential deviations that may result in the exclusion of a participant from the PP population for specific immunogenicity analyses (depending on the time point) include:

- Failure to receive study vaccine at Visit 5 (Week 8)
- Receipt of a prohibited medication or prohibited vaccine prior to a blood sample collection
- Collection of a blood sample outside the prespecified window

The final determination on protocol deviations, and thereby the composition of the PP population, will be made prior to the final unblinding of the database. Participants will be included in the vaccination group to which they are randomized for the analysis of immunogenicity data using the PP population.

A supportive analysis using the FAS population will also be performed for the primary immunogenicity endpoint. The FAS population consists of all randomized participants who received at least 1 study vaccination and have at least 1 serology result. Participants will be included in the vaccination group to which they are randomized for the analysis of immunogenicity data using the FAS population.

Part B

The PP population consists of participants administered V116 in Part A without deviations from the protocol that may substantially affect the results of the immunogenicity endpoints. Potential deviations that may result in the exclusion of a participant from the PP population for all immunogenicity analyses include:

- Failure to receive PCV15 at Visit 9 (Day 1B)
- Receipt of a prohibited medication or prohibited vaccine prior to PCV15 vaccination at Visit 9 (Day 1B)

Additional potential deviations that may result in the exclusion of a participant from the PP population for specific immunogenicity analyses include:

- Receipt of a prohibited medication or prohibited vaccine prior to a blood sample collection
- Collection of a blood sample outside the prespecified window

The final determination on protocol deviations, and thereby the composition of the PP population, will be made prior to the planned Part B analysis.

9.5.2 Safety Analysis Populations

Part A and Part B

Safety analyses will be conducted in the APaT population, which consists of all randomized participants who received at least 1 dose of study vaccination. Participants will be included in the group corresponding to the study vaccination they actually received for the analysis of safety data using the APaT population. This will be the group to which they are randomized except for participants who receive the incorrect study vaccination; such participants will be included in the group corresponding to the study vaccination actually received.

At least 1 temperature measurement obtained after study intervention is required for inclusion in the analysis of temperature.

9.6 Statistical Methods

This is a 2-part study, and each part will be summarized separately upon completion. Part A of the study will be completed before initiation of Part B. Upon completion of Part A, the database will be locked, and the Sponsor, investigators, and participants will be unblinded.

9.6.1 Statistical Methods for Immunogenicity Analyses

This section describes the statistical methods that address the primary, secondary, and exploratory immunogenicity objectives. More details for methods related to the exploratory immunogenicity objectives will be further described in the sSAP.

Part A

Immunogenicity analyses will be conducted for each of the 21 pneumococcal serotypes in V116 separately. To address the primary immunogenicity objective, evaluation of the OPA GMTs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12) will include descriptive summaries and within-group 95% CIs for each vaccination group.

For the secondary immunogenicity objectives, to evaluate IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12), a similar statistical approach described in the primary objective will be used. Also, GMFR and proportions of participants with a ≥ 4 -fold rise for both OPA and IgG responses will be calculated for V116 (from Day 1 to Day 30) or PCV15 + PPSV23 (from Day 1 to Week 12). Descriptive statistics with point estimates and within-group 95% CIs will be provided for these endpoints.

For the continuous endpoints, the point estimates will be calculated by exponentiating the estimates of the mean of the natural log values and the within-group CIs will be derived by exponentiating the bounds of the CIs of the mean of the natural log values based on the t-distribution. For the dichotomous endpoints, the within-group CIs will be calculated based on the exact method proposed by Clopper and Pearson [CLOPPER, C. J. and PEARSON, E. S. 1934].

To address the exploratory immunogenicity objective that aims to evaluate the immune responses for V116 (Day 30) compared with PCV15 + PPSV23 (Week 12), the serotype-specific OPA GMTs will be compared between intervention groups through the estimation of serotype-specific OPA GMT ratios. Estimation of the OPA GMT ratios and computation of the corresponding 95% CIs will be calculated using a cLDA method proposed by Liang and Zeger [Liang, K-Y and Zeger, S. L. 2000]. Details regarding the cLDA models will be included in the sSAP. A similar statistical approach will be used to analyze the IgG GMCs between the 2 intervention groups.

Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be graphically displayed by serotype.

Part B

For the exploratory immunogenicity objective, evaluation of the OPA GMTs and IgG GMCs postvaccination with PCV15 (Day 30B), GMFR and proportions of participants with a ≥ 4 -fold rise for both OPA and IgG responses from Day 1B to Day 30B will be provided with within-group 95% CIs. A similar statistical approach described in the primary and secondary immunogenicity objectives in Part A will be applied.

Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be graphically displayed by serotype.

A detailed analysis strategy for immunogenicity endpoints in Part A and Part B is listed in [Table 6](#).

Table 6 Analysis Strategy for Immunogenicity Variables

Endpoint/Variable (Description, Time Point)	Primary vs. Supportive Approach ^a	Statistical Method	Analysis Population	Missing Data Approach
Primary Endpoints				
Part A: OPA GMTs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
	S		FAS	
Secondary Endpoints				
Part A: IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12)	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
Part A: GMFR and % of participants who achieved a ≥ 4 -fold rise from baseline (Day 1) to postvaccination with V116 (Day 30) or PCV15 + PPSV23 (Week 12) for both OPA and IgG responses	P	Descriptive Statistics (estimate, 95% CI)	PP	Missing data will not be imputed
CI=confidence interval; FAS=full analysis set; GMC=geometric mean concentration; GMFR=geometric mean fold rise; GMT=geometric mean titer; IgG=immunoglobulin G; OPA=opsonophagocytic activity; PP=per-protocol ^a P=primary approach; S=supportive approach				

9.6.2 Statistical Methods for Safety Analyses

Part A

Safety and tolerability will be assessed by clinical review of all relevant parameters, including AEs and postvaccination temperature measurements. The safety profile will be assessed via point estimates and 95% CIs (for select safety endpoints) across vaccination groups. Summaries on safety parameters will be provided following any vaccination and following each vaccination.

Part B

Similar statistical methods for safety assessment used in Part A will be used in Part B. In addition, summaries on key safety parameters following V116 and following PCV15 will be provided for participants who receive V116 and PCV15 on Day 1 and Day 1B, respectively.

9.6.2.1 Overall Safety Assessment

The overall safety evaluation will include a summary (ie, number and percentage) of participants with any AEs, any unsolicited AEs, any vaccine-related AEs, any SAEs, any vaccine-related SAEs, discontinuation due to an AE, and an AE resulting in death. Point

estimates and within-group 95% CIs for the percentages of participants will be provided for these events.

The number and percentage of participants with specific AEs will also be provided. Point estimates and within-group 95% CIs for the percentages of participants with specific AEs will be provided for solicited AEs and AEs that occur in $\geq 5\%$ of participants.

The number and percentage of participants with maximum temperature measurements categorized by Brighton Collaboration cut points [Marcy, S. M., et al 2004] will be provided along with point estimates and within-group 95% CIs to evaluate elevated temperatures.

Within-group CIs will be calculated using the Clopper Pearson method [CLOPPER, C. J. and PEARSON, E. S. 1934]. CIs should only be regarded as helpful descriptive measures for the review of the safety profile and not as a formal method for assessing statistical significance.

The analysis strategy for safety endpoints is provided in [Table 7](#).

Table 7 Analysis Strategy for Safety Parameters – Part A and Part B

Analysis Part	Safety Endpoint	Descriptive Statistics	Within-group 95% CI
Overall Safety Assessment	Solicited injection-site AE (Day 1 through Day 5 postvaccination) ^a	X	X
	Solicited systemic AE (Day 1 through Day 5 postvaccination) ^a	X	X
	Any AE ^b	X	X
	Any unsolicited AE ^b	X	X
	Any vaccine-related AE ^b	X	X
	Any SAE ^b	X	X
	Any vaccine-related SAE ^b	X	X
	Discontinuation due to AE ^b	X	X
	Death ^b	X	X
	Specific AEs by SOC and PT ^c	X	X
Maximum temperature (Day 1 through Day 5 postvaccination) ^d	X	X	

AE=adverse event; CI=confidence interval; PT=preferred term; SAE=serious adverse event; SOC=system organ class

^a Solicited injection-site AEs include redness/erythema, swelling, and tenderness/pain; solicited systemic AEs include muscle aches all over body/myalgia, headache, and tiredness/fatigue.

^b These endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of “Any AE” will provide the number and percentage of participants with at least 1 AE.

^c Descriptive statistics will be provided for specific AEs with incidence >0% of participants in any vaccination group; additionally within-group 95% CIs will be provided for specific AEs within $\geq 5\%$ of participants in any vaccination group.

^d Maximum temperature measurements are categorized by Brighton Collaboration cut points.

9.6.3 Demographic and Baseline Characteristics

The comparability of the vaccination groups for each relevant demographic and baseline characteristic will be assessed by the use of summary tables. No statistical hypothesis tests will be performed on these characteristics. The number and percentage of participants screened and randomized and the primary reasons for screening failure and discontinuation will be displayed. Demographic variables (eg, age, race, ethnicity, sex, and gender), baseline characteristics, and prior and concomitant vaccinations and therapies will be summarized by vaccination group either by descriptive statistics or categorical tables.

9.7 Interim Analyses

Part A and Part B

A periodic review of safety and tolerability data across the V116 Phase 3 adult program will be conducted by an independent, unblinded, external DMC. A description of the structure and function of the DMC, along with the timing and content of the safety review, will be outlined in the DMC charter. Information regarding the composition of the DMC is provided in Appendix 1. Unblinded immunogenicity data will be made available to the DMC upon request to enable a benefit-risk assessment.

The DMC will serve as the primary reviewer of the results of the ongoing safety reviews and will make recommendations for discontinuation of the study or protocol modifications to an EOC of the Sponsor (see Appendix 1 for details on the Committees Structure for this study). If the DMC recommends modifications to the design of the protocol or discontinuation of the study, the EOC of the Sponsor (and potentially other limited Sponsor personnel) may be unblinded to results at the intervention level to act on these recommendations. The extent to which individuals are unblinded with respect to ongoing safety reviews will be documented by the external unblinded statistician. Additional logistical details will be provided in the DMC charter.

Study enrollment may be ongoing at the time of external DMC review. Blinding to intervention assignment will be maintained at all investigational sites. Participant-level unblinding will be restricted to an external unblinded statistician performing ongoing safety reviews. Intervention-level ongoing safety reviews will be provided by the external unblinded statistician to the DMC. Prior to final study unblinding, the external unblinded statistician will not be involved in any discussions regarding modifications to the protocol, statistical methods, identification of protocol deviations, or data validation efforts after the safety reviews.

9.8 Multiplicity

No multiplicity adjustment is planned as there is no hypothesis testing.

9.9 Sample Size and Power Calculations

9.9.1 Sample Size and Power for Immunogenicity Analyses

This is a descriptive study. This study will randomize approximately 150 participants into the V116 + placebo group and 150 participants into the PCV15 + PPSV23 group. It is assumed that 135 participants per vaccination group will be evaluable for PP immunogenicity analyses based on a 90% evaluability rate.

The width of the within-group 95% CIs for the serotype-specific OPA GMTs depend on the sample size, variability of the natural log titers, and the magnitude of the OPA GMTs. The 95% CIs for various hypothetical OPA GMTs and various hypothetical standard deviation estimates for the natural log titers are displayed in [Table 8](#).

Table 8 Within-group 95% CIs for Varying Hypothetical OPA GMTs and Varying Standard Deviations With 135 Evaluable Participants in Each Vaccination Group

Standard Deviation of Natural Log Titers ^a	Serotype-specific OPA GMT ^a		
	500	1000	5000
1.0	(422, 593)	(843, 1186)	(4217, 5928)
1.5	(387, 645)	(775, 1291)	(3873, 6454)
2.0	(356, 703)	(711, 1406)	(3557, 7028)
2.5	(327, 765)	(653, 1530)	(3267, 7652)

CI=confidence interval; GMT=geometric mean titer; OPA=opsonophagocytic activity
^a The estimates of the standard deviation and OPA GMTs are representative of those observed in V116-001.

9.9.2 Sample Size and Power for Safety Analyses

The sample size was selected to achieve a reasonably sized safety database in this population exposed to V116. The probability of observing at least 1 SAE in this study depends on the number of participants vaccinated and the underlying incidence of participants with a SAE in the study population. Calculations below assume that 100% of the randomized participants will be evaluable for safety analyses. There is an 80% chance of observing at least 1 SAE among 150 participants in the V116 group if the underlying incidence of a SAE is 1.07% (1 of every 93 participants receiving the vaccine). There is a 50% chance of observing at least 1 SAE among 150 participants in the V116 group if the underlying incidence of a SAE is 0.46% (1 of every 216 participants receiving the vaccine). If no SAEs are observed among the 150 participants in the V116 group, this study will provide 97.5% confidence that the underlying percentage of participants with a SAE is <2.44% (1 in every 40 participants) in the V116 group.

9.10 Subgroup Analyses

Part A

Serotype-specific OPA GMTs and their corresponding within-group 95% CIs for V116 (Day 30) or PCV15 + PPSV23 (Week 12) will be calculated within each vaccination group for each subgroup of the following classification variables:

- Age category (18 to <50; \geq 50 years of age)
- Sex
- Race
- Ethnicity
- Prior pneumococcal vaccination status (PCV13 and PPSV23 naïve; prior PCV13 only, prior PPSV23 only, or prior PCV13 and PPSV23)
- CD4+ T-cell count at Screening (\geq 50 to <500; \geq 500 cells/ μ L)
- Time since receipt of last pneumococcal vaccination for PCV13 and/or PPSV23 experienced participants:
 - Prior PCV13 only (\geq 8 weeks to <5 years; \geq 5 years)
 - Prior PPSV23 only or prior PCV13 and PPSV23 (4 to 9 years; \geq 10 years)

In addition, a summary of AEs and a summary of solicited AEs will be provided for each of the subgroups listed above (point estimates only).

Further details of subgroup analyses will be documented in the sSAP.

9.11 Compliance (Medication Adherence)

Given that participants will receive a single dose of V116 or PCV15, followed by a single dose of placebo or PPSV23 in Part A, respectively, and the V116 recipients in Part A will receive a single dose of PCV15 in Part B, compliance will not be calculated. However, the number and proportion of randomized participants receiving each vaccination will be summarized (Section 9.12).

9.12 Extent of Exposure

The extent of exposure will be summarized by the number and proportion of randomized participants administered V116, placebo, PCV15, or PPSV23 in Part A and by the number and proportion of participants administered PCV15 in Part B.

10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations

10.1.1 Code of Conduct for Clinical Trials

Merck Sharp & Dohme LLC, Rahway, NJ, USA (MSD)

Code of Conduct for Interventional Clinical Trials

I. Introduction

A. Purpose

MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted in compliance with local and/or national regulations (including all applicable data protection laws and regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in accordance with the ethical principles that have their origin in the Declaration of Helsinki.

B. Scope

Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the full control of MSD.

II. Scientific Issues

A. Trial Conduct

1. Trial Design

Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine patient preferences, etc.

The design (i.e., participant population, duration, statistical power) must be adequate to address the specific purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where applicable, third parties. All trial protocols are and will be assessed for the need and capability to enroll underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial.

2. Site Selection

MSD's clinical trials are conducted globally in many different countries and in diverse populations, including people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability to successfully conduct the trial.

Where appropriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage underrepresented groups and those disproportionately impacted by the disease under study. MSD will support clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately use the products under investigation.

3. Site Monitoring/Scientific Integrity

Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice (GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus source documentation according to standard operating procedures. Per MSD policies and procedures, if potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective and/or preventative actions are defined and regulatory authorities and/or ethics review committees are notified.

B. Publication and Authorship

Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be underpowered and the analyses complicated by statistical issues such as multiplicity.

MSD's policy on authorship is consistent with the recommendations published by the International Committee of Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in publications.

III. Participant Protection

A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics Committee [IEC])

All protocols and protocol amendments will be submitted by MSD for regulatory authority acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or national regulations.

The protocol, protocol amendment(s), informed consent form, investigator's brochure, and other relevant trial documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with local and/or national regulations.

B. Safety

The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial designs will take into account the local standard of care.

All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or receipt of, medical care that may otherwise be available to them.

C. Confidentiality

MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records that might identify the participant by name.

D. Genomic Research

Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an ethics committee.

IV. Financial Considerations

A. Payments to Investigators

Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be made to compensate for the time spent in extra recruiting efforts.

MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent on chart review and medical evaluation to identify potentially eligible participants.

B. Clinical Research Funding

Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring institution is being paid or provided a grant for performing the trial. However, the local ethics committee may wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.

C. Funding for Travel and Other Requests

Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be consistent with local guidelines and practices.

V. Investigator Commitment

Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the protocol, agree to support these ethical and scientific standards.

10.1.2 Financial Disclosure

Financial disclosure requirements are outlined in the US Food and Drug Administration Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the Sponsor's responsibility to determine, based on these regulations, whether a request for financial disclosure information is required. It is the investigator's/subinvestigator's responsibility to comply with any such request.

The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to allow for the submission of complete and accurate certification and disclosure statements. The investigator/subinvestigator(s) further agree to provide this information on a Certification/Disclosure Form, frequently known as a financial disclosure form, provided by the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this

information to the Sponsor in the United States for these purposes. This may involve the transmission of information to countries that do not have laws protecting personal data.

10.1.3 Data Protection

The Sponsor will conduct this study in compliance with all applicable data protection regulations.

Participants will be assigned a unique identifier by the Sponsor. Any participant records or datasets that are transferred to the Sponsor will contain the identifier only; participant names or any information that would make the participant identifiable will not be transferred.

The participant must be informed that his/her personal study-related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant.

The participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.

10.1.3.1 Confidentiality of Data

By signing this protocol, the investigator affirms to the Sponsor that information furnished to the investigator by the Sponsor will be maintained in confidence, and such information will be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and employees, only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees. Data generated by this study will be considered confidential by the investigator, except to the extent that it is included in a publication as provided in the Publications section of this protocol.

10.1.3.2 Confidentiality of Participant Records

By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to verify worksheet/CRF data. By signing the consent form, the participant agrees to this process. If study documents will be photocopied during the process of verifying worksheet/CRF information, the participant will be identified by unique code only; full names/initials will be masked before transmission to the Sponsor.

By signing this protocol, the investigator agrees to treat all participant data used and disclosed in connection with this study in accordance with all applicable privacy laws, rules and regulations.

10.1.3.3 Confidentiality of IRB/IEC Information

The Sponsor is required to record the name and address of each IRB/IEC that reviews and approves this study. The Sponsor is also required to document that each IRB/IEC meets regulatory and ICH GCP requirements by requesting and maintaining records of the names

and qualifications of the IRB/IEC members and to make these records available for regulatory agency review upon request by those agencies.

10.1.4 Committees Structure

10.1.4.1 Executive Oversight Committee

The EOC is comprised of members of Sponsor Senior Management. The EOC will receive and decide on any recommendations made by the DMC regarding the study.

10.1.4.2 External Data Monitoring Committee

To supplement the routine study monitoring outlined in this protocol, an external DMC will monitor the interim data from this study. The voting members of the committee are external to the Sponsor. The members of the DMC must not be involved with the study in any other way (eg, they cannot be study investigators) and must have no competing interests that could affect their roles with respect to the study.

The DMC will make recommendations to the EOC regarding steps to ensure both participant safety and the continued ethical integrity of the study. Also, the DMC will review interim study results, consider the overall risk and benefit to study participants (Section 9.7) and recommend to the EOC whether the study should continue in accordance with the protocol.

Specific details regarding composition, responsibilities, and governance, including the roles and responsibilities of the various members and the Sponsor protocol team; meeting facilitation; the study governance structure; and requirements for and proper documentation of DMC reports, minutes, and recommendations will be described in the DMC charter that is reviewed and approved by all the DMC members.

10.1.4.3 Scientific Advisory Committee (SAC)

This study was developed in collaboration with a SAC. The SAC is comprised of both Sponsor and non-Sponsor scientific experts who provide scientific and strategic guidance on various aspects of the clinical trial and/or development, which may include study design, interpretation of study results, and subsequent peer-reviewed scientific publications.

10.1.5 Publication Policy

The results of this study may be published or presented at scientific meetings. The Sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator will be designated by mutual agreement.

If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.

Authorship will be determined by mutual agreement and in line with ICMJE authorship requirements.

10.1.6 Compliance with Study Registration and Results Posting Requirements

Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the Sponsor of the study is solely responsible for determining whether the study and its results are subject to the requirements for submission to <http://www.clinicaltrials.gov>, www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will review this protocol and submit the information necessary to fulfill these requirements. MSD entries are not limited to FDAAA or the EMA clinical trials directive mandated trials. Information posted will allow participants to identify potentially appropriate studies for their disease conditions and pursue participation by calling a central contact number for further information on appropriate study locations and study-site contact information.

By signing this protocol, the investigator acknowledges that the statutory obligations under FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the Sponsor and agrees not to submit any information about this study or its results to those registries.

10.1.7 Compliance with Law, Audit, and Debarment

By signing this protocol, the investigator agrees to conduct the study in an efficient and diligent manner and in conformance with this protocol; generally accepted standards of GCP (eg, ICH GCP: Consolidated Guideline and other generally accepted standards of GCP); and all applicable federal, state and local laws, rules and regulations relating to the conduct of the clinical study.

The Code of Conduct, a collection of goals and considerations that govern the ethical and scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix under the Code of Conduct for Clinical Trials.

The investigator agrees not to seek reimbursement from participants, their insurance providers, or from government programs for procedures included as part of the study reimbursed to the investigator by the Sponsor.

The investigator will promptly inform the Sponsor of any regulatory authority inspection conducted for this study.

The investigator agrees to provide the Sponsor with relevant information from inspection observations/findings to allow the Sponsor to assist in responding to any citations resulting from regulatory authority inspection and will provide the Sponsor with a copy of the proposed response for consultation before submission to the regulatory authority.

Persons debarred from conducting or working on clinical studies by any court or regulatory authority will not be allowed to conduct or work on this Sponsor's studies. The investigator will immediately disclose in writing to the Sponsor if any person who is involved in

conducting the study is debarred or if any proceeding for debarment is pending or, to the best of the investigator's knowledge, threatened.

10.1.8 Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator or qualified designee is responsible for verifying that data entries are accurate and correct by physically or electronically signing the CRF.

Detailed information regarding Data Management procedures for this protocol will be provided separately.

The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.

The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory agency inspections and provide direct access to source data documents.

Study documentation will be promptly and fully disclosed to the Sponsor by the investigator upon request and also shall be made available at the study site upon request for inspection, copying, review, and audit at reasonable times by representatives of the Sponsor or any regulatory authorities. The investigator agrees to promptly take any reasonable steps that are requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to cure deficiencies in the study documentation and worksheets/CRFs.

The Sponsor or designee is responsible for the data management of this study including quality checking of the data.

Study monitors will perform ongoing source data review and verification to confirm that data entered into the CRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.

Records and documents, including participants' documented informed consent, pertaining to the conduct of this study must be retained by the investigator for 15 years after study completion unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.

10.1.9 Source Documents

Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. The investigator/institution should maintain adequate and accurate source documents and study records that include all pertinent observations on each

of the site's participants. Source documents and data should be attributable, legible, contemporaneous, original, accurate, and complete. Changes to source data should be traceable, should not obscure the original entry, and should be explained if necessary (eg, via an audit trail). Source documents are filed at the investigator's site.

Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator/institution may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.

10.1.10 Study and Site Closure

The Sponsor or its designee may stop the study or study-site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and GCP.

In the event the Sponsor prematurely terminates a particular study site, the Sponsor or designee will promptly notify that study site's IRB/IEC as specified by applicable regulatory requirement(s).

10.2 Appendix 2: Clinical Laboratory Tests

- The pregnancy testing (Table 9) will be performed by the local laboratory and HIV serology, CD4+ T-cell count, and plasma HIV RNA testing will be performed by the central laboratory.
- Protocol-specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.
- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.

Table 9 Protocol-required Safety Laboratory Assessments

Laboratory Assessments	Parameters
Pregnancy Testing	<ul style="list-style-type: none">• Highly sensitive serum or urine hCG pregnancy test (as needed for WOCBP)
Other Screening Tests	<ul style="list-style-type: none">• Serum for HIV Serology• Blood sample for CD4+ T-cell count and plasma HIV RNA testing

hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; RNA=ribonucleic acid; WOCBP=women of childbearing potential

The investigator (or medically qualified designee) must document their review of each laboratory safety report.

10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting

10.3.1 Definitions of Medication Error, Misuse, and Abuse

Medication error

This is an unintended failure in the drug treatment process that leads to or has the potential to lead to harm to the patient.

Misuse

This refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the terms of the product information.

Abuse

This corresponds to the persistent or sporadic, intentional excessive use of a medicinal product for a perceived psychological or physiological reward or desired nontherapeutic effect.

10.3.2 Definition of AE

AE definition

- An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Note: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
- Note: For purposes of AE definition, study intervention (also referred to as Sponsor's product) includes any pharmaceutical product, biological product, vaccine, diagnostic agent, medical device, combination product, or protocol specified procedure whether investigational or marketed (including placebo, active comparator product, or run-in intervention), manufactured by, licensed by, provided by, or distributed by the Sponsor for human use in this study.

Events meeting the AE definition

- Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the investigator.

- Exacerbation of a chronic or intermittent preexisting condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or a concomitant medication.
- For all reports of overdose (whether accidental or intentional) with an associated AE, the AE term should reflect the clinical symptoms or abnormal test result. An overdose without any associated clinical symptoms or abnormal laboratory results is reported using the terminology “accidental or intentional overdose without adverse effect.”
- Any new cancer or progression of existing cancer.

Events NOT meeting the AE definition

- Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.
- Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).
- Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Surgical procedure(s) planned prior to informed consent to treat a preexisting condition that has not worsened.
- Refer to Section 8.4.6 for protocol-specific exceptions.

Definition of Unsolicited and Solicited AE

- An unsolicited AE is an AE that was not solicited using a VRC and that is communicated by a participant/participant’s legally authorized representative who has signed the informed consent. Unsolicited AEs include serious and nonserious AEs.
- Solicited AEs are predefined local (at the injection/administration site) and systemic events for which the participant/participant’s legally authorized representative is specifically questioned, and which are noted by the participant/participant’s legally authorized representative in their VRC.

10.3.3 Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met.

An SAE is defined as any untoward medical occurrence that, at any dose:

a. Results in death

b. Is life-threatening

- The term “life-threatening” in the definition of “serious” refers to an event in which the participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.

c. Requires inpatient hospitalization or prolongation of existing hospitalization

- Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a preexisting condition that has not worsened is not an SAE.) A preexisting condition is a clinical condition that is diagnosed prior to the use of an MSD product and is documented in the participant’s medical history.

d. Results in persistent or significant disability/incapacity

- The term disability means a substantial disruption of a person’s ability to conduct normal life functions.
- This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.

e. Is a congenital anomaly/birth defect

- In offspring of participant taking the product regardless of time to diagnosis.

f. Other important medical events

- Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the other outcomes listed in the above definition. These events should usually be considered serious.

- Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.

10.3.4 Additional Events Reported

Additional events that require reporting

In addition to the above criteria, AEs meeting either of the below criteria, although not serious per ICH definition, are reportable to the Sponsor.

- Is a cancer
- Is associated with an overdose

10.3.5 Recording AE and SAE

AE and SAE recording

- When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to the event.
- The investigator will record all relevant AE/SAE information on the AE CRFs/worksheets at each examination.
- It is not acceptable for the investigator to send photocopies of the participant's medical records to the Sponsor in lieu of completion of the AE CRF page.
- There may be instances when copies of medical records for certain cases are requested by the Sponsor. In this case, all participant identifiers, with the exception of the participant number, will be blinded on the copies of the medical records before submission to the Sponsor.
- The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.

Assessment of intensity

- An event is defined as "serious" when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, not when it is rated as severe.
- The investigator will make an assessment of overall intensity grade for each AE and SAE (and other reportable event) reported during the study. An overall intensity grade will be assigned to injection-site AEs, specific systemic AEs, other systemic AEs, and vital sign (temperature) AEs as shown in the following tables. The overall intensity grading scales

used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Injection-site AE Overall Intensity Grading Scale

Injection-site Reaction to Study Vaccine/Placebo	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Injection-site AEs occurring Day 1 through Day 5 following receipt of study vaccine/placebo				
Pain/Tenderness	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Erythema/Redness	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or exfoliative dermatitis or results in ER visit or hospitalization
Swelling	Size measured as ≤5 cm	Size measured as 5.1 to 10 cm	Size measured as >10 cm	Necrosis or ER visit or hospitalization
Other	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Any injection-site reaction that begins ≥6 days after receipt of study vaccine/placebo				
Pain/Tenderness Erythema/Redness Swelling Other	Does not interfere with activity	Repeated use of non-narcotic pain reliever >24 hours or interferes with activity	Any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization

AE=adverse event; ER=emergency room

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Specific Systemic AE Overall Intensity Grading Scale

Systemic (General)	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Headache	No interference with activity	Repeated use of non-narcotic pain reliever >24 hours or some interference with activity	Significant; any use of narcotic pain reliever or prevents daily activity	ER visit or hospitalization
Fatigue	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalization
Myalgia	No interference with activity	Some interference with activity	Significant; prevents daily activity	ER visit or hospitalization

ER=emergency room

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

Other Systemic AE Overall Intensity Grading Scale

Systemic Illness ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4) ^b
Illness or clinical AE (as defined according to applicable regulations)	No interference with activity	Some interference with activity not requiring medical intervention	Prevents daily activity and required medical intervention	ER visit or hospitalization

AE=adverse event; ER=emergency room; eVRC=electronic Vaccine Report Card; SAE=serious adverse event

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Based upon information provided by the participant on the eVRC and verbally during the eVRC review during the primary safety follow-up period. For SAEs reported beyond the primary safety follow-up period, grading will be based upon the initial report and/or follow-up of the event.

^b AEs resulting in death will be assessed as Grade 4.

Vital Sign (Temperature) Overall Intensity Grading Scale

Vital Signs ^a	Mild (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Potentially Life Threatening (Grade 4)
Fever (°C) ^b	38.0 to 38.4	38.5 to 38.9	39.0 to 40.0	>40.0
(°F) ^b	100.4 to 101.1	101.2 to 102.0	102.1 to 104.0	>104.0

The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food and Drug Administration 2007].

^a Participant should be at rest for all vital sign requirements.

^b Oral temperature; no recent hot or cold beverages or smoking.

Assessment of causality

- Did the Sponsor’s product cause the AE?
- The determination of the likelihood that the Sponsor’s product caused the AE will be provided by an investigator who is a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test product and the AE based upon the available information.
- **The following components are to be used to assess the relationship between the Sponsor’s product and the AE;** the greater the correlation with the components and their respective elements (in number and/or intensity), the more likely the Sponsor’s product caused the AE:
 - **Exposure:** Is there evidence that the participant was actually exposed to the Sponsor’s product such as: reliable history, acceptable compliance assessment (diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
 - **Time Course:** Did the AE follow in a reasonable temporal sequence from administration of the Sponsor’s product? Is the time of onset of the AE compatible with a vaccine-induced effect?
 - **Likely Cause:** Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental factors?
 - **Rechallenge:** Was the participant re-exposed to the Sponsor’s product in the study?
 - If yes, did the AE recur or worsen?
 - If yes, this is a positive rechallenge.
 - If no, this is a negative rechallenge.

(Note: This criterion is not applicable if: (1) the initial AE resulted in death or permanent disability, or (2) the study is a single-dose vaccine study; or (3) Sponsor's product(s) is/are used only 1 time.)

NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE IRB/IEC.

- **Consistency with study intervention profile:** Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class pharmacology or toxicology?
- The assessment of relationship will be reported on the CRFs/worksheets by an investigator who is a qualified physician according to their best clinical judgment, including consideration of the above elements.
- Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
 - Yes, there is a reasonable possibility of Sponsor's product relationship:
 - There is evidence of exposure to the Sponsor's product. The temporal sequence of the AE onset relative to the administration of the Sponsor's product is reasonable. The AE is more likely explained by the Sponsor's product than by another cause.
 - No, there is not a reasonable possibility of Sponsor's product relationship:
 - Participant did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not reasonable OR the AE is more likely explained by another cause than the Sponsor's product. (Also entered for a participant with overdose without an associated AE.)
- The investigator must review and provide an assessment of causality for each AE/SAE and document this in the medical notes.
- There may be situations in which an SAE has occurred and the investigator has minimal information to include in the initial report to the Sponsor. However, it is very important that the investigator always make an assessment of causality for every event before the initial transmission of the SAE data to the Sponsor.
- The investigator may change their opinion of causality in light of follow-up information and send an SAE follow-up report with the updated causality assessment.

- The causality assessment is 1 of the criteria used when determining regulatory reporting requirements.

Follow-up of AE and SAE

- The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.
- New or updated information will be recorded in the CRF.
- The investigator will submit any updated SAE data to the Sponsor within 24 hours of receipt of the information.

10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor

AE, SAE, and other reportable safety event reporting to Sponsor via electronic data collection tool

- The primary mechanism for reporting to the Sponsor will be the EDC tool.
 - Electronic reporting procedures can be found in the EDC data entry guidelines (or equivalent).
 - If the electronic system is unavailable for more than 24 hours, then the site will use the paper AE Reporting form.
 - Reference Section 8.4.1 for reporting time requirements.
- The site will enter the SAE data into the electronic system as soon as it becomes available.
- After the study is completed at a given site, the EDC tool will be taken off-line to prevent the entry of new data or changes to existing data.
- If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the EDC tool has been taken off-line, then the site can report this information on a paper SAE form or by telephone (see next section).
- Contacts for SAE reporting can be found in the Investigator Study File Binder (or equivalent).

SAE reporting to the Sponsor via paper CRF

- If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE paper CRF is the preferred method to transmit this information to the Sponsor.
- In rare circumstances and in the absence of facsimile equipment, notification by telephone is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
- Initial notification via telephone does not replace the need for the investigator to complete and sign the SAE CRF pages within the designated reporting time frames.
- Contacts and instructions for SAE reporting and paper reporting procedures can be found in the Investigator Study File Binder (or equivalent).

10.4 Appendix 4: Medical Device and Drug-device Combination Products: Product Quality Complaints/Malfunctions: Definitions, Recording, and Follow-up

The recording and follow-up procedures described in this protocol apply to all medical devices as described below. For purposes of this section, medical devices in scope for device information collection include devices intended to be used by a study participant according to the study protocol, that are manufactured by the Sponsor or for the Sponsor by a third party, licensed by the Sponsor for human use and/or drug-device combination products as listed in Section 6.1.1. Product Quality Complaints/Malfunctions must be reported to the Sponsor.

10.4.1 Definitions

Combination Product - A product comprised of two or more regulated components (ie, a drug and a device; a biologic and device; a biologic and a drug; or a drug, a device, and a biologic). Combination products can be single entity, copackaged, or colabeled.

Complaint - Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution. This would include PQC, AE, and customer feedback.

A complaint does not necessarily need to involve a user or any other person.

Constituent Part - A drug, device, or biological product that is part of a combination product.

Customer Feedback - A report that does not allege a PQC or defect and has no relevant safety information/untoward event associated with it (eg, goodwill or courtesy replacement, consumer preference or suggestion, remark which may suggest an improvement in the functionality or quality of a medical device or device-like features of a drug delivery system).

Malfunction - The failure of a device to meet its performance specifications or otherwise perform as intended.

Medical Device - Any instrument, apparatus, appliance, material or other article, whether used alone or in combination, including the software necessary for its proper application intended by the MANUFACTURER to be used for human beings for the purpose of:

- diagnosis, prevention, monitoring, treatment or alleviation of disease,
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap,
- investigation, replacement or modification of the anatomy or of a physiological process,
- control of conception,

and which does not achieve its principal intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.

PQC - Any communication that describes a potential defect related to the identity, strength, quality, purity or performance of a product identified by external customers. This includes potential device or device component malfunctions. Note: A report of Lack or Limited Efficacy is considered an AE rather than a PQC.

Serious Injury - An injury or illness that:

1. Is life-threatening,
2. Results in permanent impairment of a body function or permanent damage to a body structure, or
3. Necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.

Permanent means irreversible impairment or damage to a body structure or function, excluding trivial impairment or damage.

10.4.2 Recording, Assessing Causality, and Follow-up of PQCs/Malfunctions

Recording

- When a Complaint including PQC/malfunction occurs it is the responsibility of the investigator to review all documentation (eg, hospital progress notes, laboratory reports, and diagnostic reports) related to the event.
- Events occurring during the study will be recorded in the participant's medical records, in accordance with the investigator's normal clinical practice, and on the appropriate CRF (paper or electronic) as per instructions provided in the data entry guidelines. Medical device/device constituent part of drug device combination product information will be collected and reported to the Sponsor in the same time frame as SAEs as per Section 8.4.1 via CRF (paper or electronic). PQCs/malfunctions must be reported to the Sponsor.

Assessing Causality

- A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship.
- The investigator will use clinical judgement to determine the relationship.
- Alternative causes such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration should be considered and investigated.

Follow-up

- The investigator will perform or arrange for the conduct of supplemental measurements and/or evaluations as medically indicated or as requested by the Sponsor to elucidate the nature and/or causality of the event as complete as possible.

10.5 Appendix 5: Contraceptive Guidance

10.5.1 Definitions

Women of Childbearing Potential (WOCBP)

A woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below):

If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.

Women in the following categories are not considered WOCBP:

- Premenarchal
- Premenopausal female with 1 of the following:
 - Documented hysterectomy
 - Documented bilateral salpingectomy
 - Documented bilateral oophorectomy

For individuals with permanent infertility due to an alternate medical cause other than the above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

Note: Documentation can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.

- Postmenopausal female
 - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
 - A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or HRT. However, in the absence of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.
 - Females on HRT and whose menopausal status is in doubt will be required to use one of the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.

10.5.2 Contraception Requirements

<p>Contraceptives allowed during the study include^a:</p>
<p>Highly Effective Contraceptive Methods That Have Low User Dependency^b <i>Failure rate of <1% per year when used consistently and correctly.</i></p> <ul style="list-style-type: none"> • Progestogen- only contraceptive implant^c • IUS^d • Non-hormonal IUD • Bilateral tubal occlusion <p>• Azoospermic partner (vasectomized or secondary to medical cause) This is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days.</p> <p>Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview.</p>
<p>Highly Effective Contraceptive Methods That Are User Dependent^b <i>Failure rate of <1% per year when used consistently and correctly.</i></p> <ul style="list-style-type: none"> • Combined (estrogen- and progestogen- containing) hormonal contraception^c <ul style="list-style-type: none"> - Oral - Intravaginal - Transdermal - Injectable • Progestogen-only hormonal contraception^c <ul style="list-style-type: none"> - Oral - Injectable
<p>Sexual Abstinence</p> <ul style="list-style-type: none"> • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
<p>Methods That Are Not Considered Highly Effective <i>Failure rate of >1% per year when used consistently and correctly.</i></p> <ul style="list-style-type: none"> • Progesterone-only hormonal contraception where inhibition of ovulation is not the primary mode of action • Male or female condom with or without spermicide • Cervical cap, diaphragm, or sponge with spermicide • A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double barrier methods). <p>^a Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical studies. ^b Typical use failure rates are higher than perfect-use failure rates (ie, when used consistently and correctly). ^c If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation. ^d IUS is a progestin releasing IUD.</p> <p>Note: The following are not acceptable methods of contraception:</p> <ul style="list-style-type: none"> - Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM. - Male and female condom should not be used together (due to risk of failure with friction).

Country-specific contraception requirements are included in Appendix 7.

10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical Research

1. Definitions

- a. Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.¹
- b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as related to drug/vaccine response.²
- c. Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of variations in DNA sequence on drug/vaccine response.²
- d. DNA: Deoxyribonucleic acid.
- e. RNA: Ribonucleic acid.

2. Scope of Future Biomedical Research^{3, 4}

The specimens consented and/or collected in this study as outlined in Section 8.9 will be used in various experiments to understand:

- a. The biology of how drugs/vaccines work
- b. Biomarkers responsible for how a drug/vaccine enters and is removed by the body
- c. Other pathways with which drugs/vaccines may interact
- d. The biology of disease

The specimen(s) may be used for future assay development and/or drug/vaccine development.

It is now well recognized that information obtained from studying and testing clinical specimens offers unique opportunities to enhance our understanding of how individuals respond to drugs/vaccines, enhance our understanding of human disease and ultimately improve public health through development of novel treatments targeted to populations with the greatest need. All specimens will be used by the Sponsor or those working for or with the Sponsor.

3. Summary of Procedures for Future Biomedical Research^{3, 4}

- a. Participants for Enrollment

All participants enrolled in the clinical study will be considered for enrollment in future biomedical research.

b. Informed Consent

Informed consent for specimens (ie, DNA, RNA, protein, etc) will be obtained during screening for protocol enrollment from all participants or legal guardians, at a study visit by the investigator or his or her designate. Informed consent for future biomedical research should be presented to the participants on the visit designated in the SoA. If delayed, present consent at next possible Participant Visit. Consent forms signed by the participant will be kept at the clinical study site under secure storage for regulatory reasons.

A template of each study site's approved informed consent will be stored in the Sponsor's clinical document repository.

c. eCRF Documentation for Future Biomedical Research Specimens

Documentation of participant consent for future biomedical research will be captured in the eCRFs. Any specimens for which such an informed consent cannot be verified will be destroyed.

d. Future Biomedical Research Specimen(s)

Collection of specimens for future biomedical research will be performed as outlined in the SoA. In general, if additional blood specimens are being collected for future biomedical research, these will usually be obtained at a time when the participant is having blood drawn for other study purposes.

4. Confidential Participant Information for Future Biomedical Research^{3, 4}

In order to optimize the research that can be conducted with future biomedical research specimens, it is critical to link participants' clinical information with future test results. In fact, little or no research can be conducted without connecting the clinical study data to the specimen. The clinical data allow specific analyses to be conducted. Knowing participant characteristics like sex, age, medical history and intervention outcomes are critical to understanding clinical context of analytical results.

To maintain privacy of information collected from specimens obtained for future biomedical research, the Sponsor has developed secure policies and procedures. All specimens will be single-coded per ICH E15 guidelines as described below.

At the clinical study site, unique codes will be placed on the future biomedical research specimens. This code is a random number which does not contain any personally identifying information embedded within it. The link (or key) between participant identifiers and this unique code will be held at the study site. No personal identifiers will appear on the specimen tube.

5. Biorepository Specimen Usage^{3,4}

Specimens obtained for the Sponsor will be used for analyses using good scientific practices. Analyses using the future biomedical research specimens may be performed by the Sponsor, or an additional third party (eg, a university investigator) designated by the Sponsor. The investigator conducting the analysis will follow the Sponsor's privacy and confidentiality requirements. Any contracted third party analyses will conform to the specific scope of analysis outlined in future biomedical research protocol and consent. Future biomedical research specimens remaining with the third party after specific analysis is performed will be reported to the Sponsor.

6. Withdrawal From Future Biomedical Research^{3,4}

Participants may withdraw their consent for FBR and ask that their biospecimens not be used for FBR. Participants may withdraw consent at any time by contacting the study investigator. If medical records for the study are still available, the investigator will contact the Sponsor using the designated mailbox (clinical.specimen.management@MSD.com). Subsequently, the participant's specimens will be flagged in the biorepository and restricted to study use only. If specimens were collected from study participants specifically for FBR, these specimens will be removed from the biorepository and destroyed. Documentation will be sent to the investigator confirming withdrawal and/or destruction, if applicable. It is the responsibility of the investigator to inform the participant of completion of the withdrawal and/or destruction, if applicable. Any analyses in progress at the time of request for withdrawal/destruction or already performed before the request being received by the Sponsor will continue to be used as part of the overall research study data and results. No new analyses would be generated after the request is received.

If the medical records for the study are no longer available (eg, if the investigator is no longer required by regulatory authorities to retain the study records) or the specimens have been completely anonymized, there will no longer be a link between the participant's personal information and their specimens. In this situation, the request for withdrawal of consent and/or destruction cannot be processed.

7. Retention of Specimens^{3,4}

Future biomedical research specimens will be stored in the biorepository for potential analysis for up to 20 years from the end of the study. Specimens may be stored for longer if a regulatory or governmental authority has active questions that are being answered. In this special circumstance, specimens will be stored until these questions have been adequately addressed.

Specimens from the study site will be shipped to a central laboratory and then shipped to the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular study, the study site will ship directly to the Sponsor-designated biorepository. The specimens will be stored under strict supervision in a limited access facility which operates to assure the integrity of the specimens. Specimens will be destroyed according

to Sponsor policies and procedures and this destruction will be documented in the biorepository database.

8. Data Security^{3,4}

Databases containing specimen information and test results are accessible only to the authorized Sponsor representatives and the designated study administrator research personnel and/or collaborators. Database user authentication is highly secure, and is accomplished using network security policies and practices based on international standards to protect against unauthorized access.

9. Reporting of Future Biomedical Research Data to Participants^{3,4}

No information obtained from exploratory laboratory studies will be reported to the participant, family, or physicians. Principle reasons not to inform or return results to the participant include: lack of relevance to participant health, limitations of predictive capability, and concerns regarding misinterpretation.

If important research findings are discovered, the Sponsor may publish results, present results in national meetings, and make results accessible on a public website in order to rapidly report this information to doctors and participants. Participants will not be identified by name in any published reports about this study or in any other scientific publication or presentation.

10. Future Biomedical Research Study Population^{3,4}

Every effort will be made to recruit all participants diagnosed and treated on Sponsor clinical studies for future biomedical research.

11. Risks Versus Benefits of Future Biomedical Research^{3,4}

For future biomedical research, risks to the participant have been minimized and are described in the future biomedical research informed consent.

The Sponsor has developed strict security, policies, and procedures to address participant data privacy concerns. Data privacy risks are largely limited to rare situations involving possible breach of confidentiality. In this highly unlikely situation, there is risk that the information, like all medical information, may be misused.

12. Questions

Any questions related to the future biomedical research should be emailed directly to clinical.specimen.management@MSD.com.

13. References

1. National Cancer Institute [Internet]: Available from <https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618>
2. International Council on Harmonisation [Internet]: E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. Available from <http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-and-sample-cod.html>
3. Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>
4. Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at <http://i-pwg.org/>

10.7 Appendix 7: Country-specific Requirements

10.7.1 Country-specific Requirements for France

Section 5.2 Exclusion Criteria

For study sites in France, to include country-specific timeframes for prior and concomitant therapy, the following criteria replace Exclusion Criteria 13 and 14 in Section 5.2:

13. Received immunosuppressive therapy within 6 months before vaccination, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.

14. *Received any nonlive vaccine ≤ 15 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤ 30 days after receipt of any study vaccine. **Exception:** inactivated influenza vaccine and SARS-CoV-2 mRNA or protein subunit vaccine may be administered but must be given ≥ 15 days before or after receipt of study vaccine.

To clarify the exclusion criteria for protected populations, the following criterion is added to Section 5.2:

21. Adults protected by law, persons deprived of their liberty by a judicial or administrative decision, those hospitalized without consent in accordance with local law as further defined in the informed consent form, and persons admitted to a health or social institution for purposes other than research.

Section 6.5 Concomitant Therapy

For study sites in France, to clarify and align with the France-specific exclusion criteria above, the following concomitant therapy replaces the original one in Section 6.5:

Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing study (Section 10.7.1). If there is a clinical indication for any medications or vaccinations specifically prohibited, discontinuation from study intervention may be required. The investigator should discuss any questions regarding this with the Sponsor Clinical Director. The final decision on any supportive therapy or vaccination rests with the investigator and/or the participant's primary physician. However, the decision to continue the participant on study intervention requires the mutual agreement of the investigator, the Sponsor, and the participant.

It is important to record the use of any analgesic or antipyretic medication that occurs on the day of vaccination on the eVRC and appropriate eCRF.

Listed below are specific restrictions for concomitant therapy or vaccination:

- Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
- Nonstudy vaccines may only be administered before or after the receipt of study vaccines according to the time frames specified in the Exclusion Criteria (Section 5.2).
- Receipt of systemic corticosteroids (prednisone equivalent ≥ 20 mg/day) for ≥ 14 consecutive days is prohibited from 14 days before vaccination through 30 days following vaccination. **Note:** physiologic replacement doses (prednisone equivalent of approximately 5 mg/day), topical, ophthalmic, intraarticular or soft-tissue (eg, bursa, tendon steroid injections), and inhaled/nebulized steroids are permitted.
- Receipt of immunosuppressive therapy within 6 months before vaccination, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease.
- Receipt of a blood transfusion or blood products, including immunoglobulin ≤ 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product until the Day 30 postvaccination blood draw is complete. Autologous blood transfusions are not considered an exclusion criterion.
- Receipt of any nonlive vaccine ≤ 15 days before receipt of study vaccine or is scheduled to receive any nonlive vaccine ≤ 30 days after receipt of any study vaccine. Exception: inactivated influenza vaccine and SARS-CoV-2 mRNA or protein subunit vaccine may be administered but must be given ≥ 15 days before and after receipt of study vaccine.
- Receipt of any live virus vaccine ≤ 30 days before receipt of study vaccine or is scheduled to receive any live virus vaccine ≤ 30 days after receipt of study vaccine.

Any deviation from the above requires consultation between the investigator and the Sponsor and written documentation of the collaborative decision on participant management.

Use of prior and concomitant medications/vaccinations should be recorded as described in Section 8.1.5.

Section 10.5.2 Contraception Requirements

For study sites in France, to clarify the contraception methods allowed during the study, the following table replaces Contraception Requirements in Section 10.5.2:

<p>Contraceptives allowed during the study include^a:</p>
<p>Highly Effective Contraceptive Methods That Have Low User Dependency^b <i>Failure rate of <1% per year when used consistently and correctly.</i></p>
<ul style="list-style-type: none"> • Progestogen-only subdermal contraceptive implant^c • IUS^d • Non-hormonal IUD • Bilateral tubal occlusion
<ul style="list-style-type: none"> • Azoospermic partner (vasectomized or secondary to medical cause) This is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. A spermatogenesis cycle is approximately 90 days. <p>Note: Documentation of azoospermia for a male participant can come from the site personnel's review of the participant's medical records, medical examination, or medical history interview.</p>
<p>Highly Effective Contraceptive Methods That Are User Dependent^b <i>Failure rate of <1% per year when used consistently and correctly.</i></p>
<ul style="list-style-type: none"> • Combined (estrogen- and progestogen- containing) hormonal contraception^c <ul style="list-style-type: none"> - Oral - Intravaginal - Transdermal - Injectable
<ul style="list-style-type: none"> • Progestogen-only hormonal contraception^c <ul style="list-style-type: none"> - Oral - Injectable
<p>Sexual Abstinence</p> <ul style="list-style-type: none"> • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
<p>^a Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical studies.</p> <p>^b Typical use failure rates are higher than perfect-use failure rates (ie, when used consistently and correctly).</p> <p>^c If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to those which inhibit ovulation.</p> <p>^d IUS is a progestin releasing IUD.</p> <p>Note: The following are not acceptable methods of contraception:</p> <ul style="list-style-type: none"> - Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and LAM. - Male and female condom should not be used together (due to risk of failure with friction).

10.8 Appendix 8: Abbreviations

Abbreviation	Expanded Term
ABCs	Active Bacterial Core Surveillance
ACIP	Advisory Committee on Immunization Practices
AE	adverse event
APaT	All-Participants-as-Treated
ART	antiretroviral therapy
CDC	Centers for Disease Control and Prevention
CFR	Code of Federal Regulations
CI	confidence interval
cLDA	constrained Longitudinal Data Analysis
CONSORT	Consolidated Standards of Reporting Trials
CRF	case report form
CSF	cerebrospinal fluid
CSR	Clinical Study Report
CTFG	Clinical Trial Facilitation Group
deOAc15B	de-O-acylated serotype 15B
DMC	Data Monitoring Committee
DNA	deoxyribonucleic acid
ECI	event of clinical interest
eCRF	electronic Case Report Form
EDC	electronic data collection
EEA	European Economic Area
EMA	European Medicines Agency
EOC	Executive Oversight Committee
EU	European Union
eVRC	electronic Vaccination Report Card
FAS	Full Analysis Set
FBR	Future Biomedical Research
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FSH	follicle stimulating hormone
FSR	first site ready
GCP	Good Clinical Practice
GMC	geometric mean concentration
GMFR	geometric mean fold rise
GMT	geometric mean titer
hCG	human chorionic gonadotropin
HIV	human immunodeficiency virus
HRT	hormone replacement therapy
IB	Investigator's Brochure
ICF	Informed Consent Form
ICH	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
ICMJE	International Committee of Medical Journal Editors
IEC	Independent Ethics Committee
IgG	Immunoglobulin G

Abbreviation	Expanded Term
IMP	investigational medicinal product
IND	Investigational New Drug
IPD	invasive pneumococcal disease
IRB	Institutional Review Board
IRT	interactive response technology
IUD	intrauterine device
IUS	intrauterine hormone-releasing system
LAM	lactational amenorrhea method
MOPA	Multiplexed Opsonophagocytic Assay
mRNA	messenger RNA
NIMP	noninvestigational medicinal product
NSAE	nonserious adverse event
OPA	opsonophagocytic activity
PCV	pneumococcal conjugate vaccine
PCV7	Prevnar™ (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)
PCV10	Synflorix™ (Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F)
PCV13	Prevnar 13™ (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F)
PCV15	VAXNEUVANCE™ (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F)
PCV20	Prevnar 20™ / Apexxnar™
Pn ECL	pneumococcal electrochemiluminescence
PnPs	pneumococcal polysaccharide
PP	per-protocol
PPSV23	PNEUMOVAX™23 (Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)
PQC	product quality complaint
PT	preferred term
RNA	ribonucleic acid
SAC	Scientific Advisory Committee
SAE	serious adverse event
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SLAB	supplemental laboratory test(s)
SoA	Schedule of Activities
SOC	system organ class
sSAP	supplemental Statistical Analysis Plan
SUSAR	suspected unexpected serious adverse reaction
US	United States
VRC	Vaccination Report Card
WOCBP	woman (or women) of childbearing potential

11 REFERENCES

- [Anttila, M., et al 1999] Anttila M, Voutilainen M, Jääntti V, Eskola J, Käyhty H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against *Streptococcus pneumoniae*. *Clin Exp Immunol* 1999;118(3):402-7. [03QY70]
- [Bonnave, C., et al 2019] Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. *Eur J Clin Microbiol Infect Dis*. 2019;38:785-91. [05CZ9M]
- [Burton, Robert L. and Nahm, Moon H. 2006] Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. *Clin Vaccine Immunol* 2006;13(9):1004-9. [03QT2R]
- [Castiglia P. 2014] Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. *Adv Ther*. 2014Oct;31(10):1011-44. [04P7LW]
- [Centers for Disease Control and Prevention 2010] Centers for Disease Control and Prevention. Prevention of Pneumococcal Disease Among Infants and Children - Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine; Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2010;59(RR-11):1-19. [03RSB6]
- [Centers for Disease Control and Prevention 2015] Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington (DC): Department of Health and Human Services (HHS); c2015. Chapter 6, Vaccine administration; p. 79-106. [0508PV]

[Centers for Disease Control and Prevention 2019]	Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP), summary report, October 24-25, 2018. Washington (DC): Department of Health and Human Services (HHS); 2019. 190 p.	[057YZL]
[Centre for Disease Control and Prevention 2016]	Centre for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report emerging infections program network Streptococcus pneumoniae, 2016. Atlanta (GA): Department of Health and Human Services (HHS); 2016. 1 p.	[052RDB]
[Centre for Disease Control and Prevention 2018]	Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report: emerging infections program network: Streptococcus pneumoniae, 2018. Washington (DC): Department of Health and Human Services (HHS); 2018.	[05J8JP]
[CLOPPER, C. J. and PEARSON, E. S. 1934]	Clopper CJ, Pearson ES. The use of confidence of fiducial limits illustrated in the case of the binomial. Biometrika 1934;26(4):404-13.	[03RRVC]
[Demczuk, W. H. B., et al 2013]	Demczuk WHB, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol 2013;59:778-88.	[03XKZ6]
[European Center for Disease Prevention and Control 2018]	European Center for Disease Prevention and Control. Surveillance report: annual epidemiological report for 2016: invasive pneumococcal disease. Stockholm (Sweden): European Center for Disease Prevention and Control (ECDC) 2018 Aug. 12 p.	[052RH8]
[Food and Drug Administration 2007]	Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville, MD. Sep 2007.	[05B4S4]

[Garcia Garrido, H. M., et al 2020]	Garcia Garrido HM, Mak AMR, Wit FWNM, Wong GWM, Knol MJ, Vollaard A, et al. Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting. Clin Infect Dis. 2020 July 1;71(1):41-50.	[06CWPT]
[Golden, A. R., et al 2016]	Golden AR, Adam HJ, Zhanel GG. Invasive Streptococcus pneumoniae in Canada, 2011-2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016 May 17;34(23):2527-30.	[04KWF0]
[Hicks, L. A., et al 2007]	Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998-2004. J Infect Dis 2007;196:1346-54.	[03QT0G]
[Kobayashi, M. 2021]	Kobayashi M. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Slides presented at: Advisory Committee on Immunization Practices (ACIP) meeting; 2021 Oct 20-21; Atlanta, GA.	[07XY2V]
[Kobayashi, M., et al 2022]	Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-17.	[07YPRJ]
[Liang, K-Y and Zeger, S. L. 2000]	Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya: The Indian Journal of Statistics 2000;62(Series B, Part 1):134-48.	[00V5V6]

[Marcy, S. M., et al 2004]	Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Connell Jones M, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. <i>Vaccine</i> 2004;22:551-6.	[03PVW0]
[Matanock, A. 2018]	Matanock A. Estimating pneumococcal pneumonia burden among U.S. adults and progress on the research agenda for potential policy change. Slides presented at: Advisory Committee on Immunization Practices (ACIP) Meeting; 2018 Feb 21-22; Atlanta, GA.	[05B5W5]
[Matanock, A., et al 2019]	Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged greater than or equal to 65 years: updated recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep.</i> 2019 Nov 22;68(46):1069-75.	[05D5ST]
[Miller, Elizabeth, et al 2011]	Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. <i>Lancet Infect Dis</i> 2011;11(10):760-8.	[03RKY7]
[Mohapi, L., et al 2021]	Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study. <i>AIDS</i> . In press 2021.	[07Y6B9]
[Moore, M. R., et al 2015]	Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. <i>Lancet Infect Dis.</i> 2015 Feb 3. [Epub ahead of print].	[043MRP]

[Nuorti, J. P. and Whitney, C. G. 2010]	Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the advisory committee on immunization practices (ACIP). MMWR 2010;59(R11):1-19.	[03RSLZ]
[Pilishvili, T. 2015]	Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Am J Prev Med. 2015 Dec;49(6 suppl 4):S383-90.	[04WP9S]
[Pilishvili, Tamara, et al 2010]	Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201(1):32-41.	[03R5S4]
[Robert Koch Institut 2017]	Robert Koch Institut. Statement of the German Standing Committee on Vaccination at the RKI: recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute - 2017/2018. Epid Bull. 2017 Aug 24;(34):333-76.	[05MFT7]
[Romero-Steiner, S., et al 1997]	Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4(4):415-22.	[03NWQ5]
[Simonsen, L., et al 2014]	Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014 May;2(5):387-94.	[04KVRV]

[Troeger, C., et al 2018]	Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Infect Dis.</i> 2018 Nov;18:1191-210.	[07XTBZ]
[U.S. Food and Drug Administration 2009]	U.S. Food and Drug Administration (CDER, CBER, CDRH). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims [Internet]. Washington: U.S. Department of Health and Human Services; 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf	[04MG9J]
[van der Linden, M., et al 2015]	van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. <i>PLoS One.</i> 2015 Jul 1;10(7):e0131494.	[04KVRVY]
[Waight, P. A., et al 2015]	Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. <i>Lancet Infect Dis.</i> 2015 May;15(5):535-43.	[04KTF2]